

TENT COOPERATION TREA

1644 1605

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

To:

MARSCHANG, Diane, L.  
Genentech, Inc.  
1 DNA Way  
South San Francisco, CA 94080-4990  
ÉTATS-UNIS D'AMÉRIQUE

FEB 10 2000

Date of mailing (day/month/year) 04 October 1999 (04.10.99)	
Applicant's or agent's file reference P1154R2	IMPORTANT NOTIFICATION
International application No. PCT/US98/21141	International filing date (day/month/year) 07 October 1998 (07.10.98)

## 1. The following indications appeared on record concerning:

☐ the applicant
                 
 ☐ the inventor
                 
 ☒ the agent
                 
 ☐ the common representative

## Name and Address

DREGER, Ginger, R.  
Genentech, Inc.  
1 DNA Way  
South San Francisco, CA 94080-4990  
United States of America

State of Nationality

State of Residence

Telephone No.

650-225-3216

Facsimile No.

650-952-9881

Teleprinter No.

## 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person
                 
 ☐ the name
                 
 ☐ the address
                 
 ☐ the nationality
                 
 ☐ the residence

## Name and Address

MARSCHANG, Diane, L.  
Genentech, Inc.  
1 DNA Way  
South San Francisco, CA 94080-4990  
United States of America

State of Nationality

State of Residence

Telephone No.

650-225-1000

Facsimile No.

650-952-9881

Teleprinter No.

## 3. Further observations, if necessary:

## 4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

Ingrid Aulich

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

16X1

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

RECEIVED

AUG 23 1999

TECH CENTER 1600/2900

in its capacity as elected Office

Date of mailing (day/month/year) 08 July 1999 (08.07.99)	Applicant's or agent's file reference P1154R2
International application No. PCT/US98/21141	Priority date (day/month/year) 17 October 1997 (17.10.97)
International filing date (day/month/year) 07 October 1998 (07.10.98)	
Applicant GODDARD, Audrey et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

14 May 1999 (14.05.99)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

Dominique DELMAS

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

2721958

PCT

REC'D 09 FEB 2000

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

09/202054

Applicant's or agent's file reference 11669.53WO01	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US98/21141	International filing date (day/month/year) 07/10/1998	Priority date (day/month/year) 17/10/1997
International Patent Classification (IPC) or national classification and IPC C12N15/12		
Applicant GENENTECH, INC. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 8 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.



23 JUN 2000

Legal Staff

International Division

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 14/05/1999	Date of completion of this report 02.02.00
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Herrmann, K  Telephone No. +49 89 2399 2670 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US98/21141

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-56 as originally filed

### Claims, No.:

1-40 as originally filed

### Drawings, sheets:

1/21-21/21 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
  - ☐ translation of the earlier application whose priority has been claimed.
2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/21141

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 3, 4, 9-14, 16, 17, 25-27, 31-36, 39, 40 and partially 1, 2, 18-30, 37, 38.

because:

- ☒ the said international application, or the said claims Nos. 37 with respect to industrial applicability relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☒ the claims, or said claims Nos. 25-27 are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 3, 4, 9-14, 16, 17, 31-36, 39, 40 and partially 1, 2, 18-30, 37, 38.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/21141

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes: Claims 1, 2, 5-8, 15, 18-24, 28-30, 37, 38
	No: Claims
Inventive step (IS)	Yes: Claims
	No: Claims 1, 2, 5-8, 15, 18-24, 28-30, 37, 38
Industrial applicability (IA)	Yes: Claims 1, 2, 5-8, 15, 18-24, 28-30, 38
	No: Claims

**2. Citations and explanations**

**see separate sheet**

**VI. Certain documents cited**

**1. Certain published documents (Rule 70.10)**

and / or

**2. Non-written disclosures (Rule 70.9)**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/21141

**Citations**

The documents mentioned in this International Preliminary Examination Report (IPER) are numbered as in the International Search Report dated 22.04.99, i.e. **D1** and **D2** correspond to the first and the last document of the search report, respectively.

**Re ITEM II (Priority)**

The priority documents pertaining to the present application were not available at the time this IPER was established.

**Re ITEM III (Non-establishment of opinion)**

- 1 The International Preliminary Examining Authority (IPEA) agrees with the objection put forward by the International Searching Authority (ISA) as to lack of unity (Rule 13 PCT) and considers that the present application relates to 4 inventions. In response to an invitation, the Applicant did not pay additional search fees. Consequently, international search and preliminary examination have been restricted to the subject-matter of claims 5-8, 15 and partially claims 1, 2, 18-30 and 37-40 ("PRO285", SEQ ID NOs:1 and 2) which the ISA identified as invention 1.
- 2 No search report was established for the subject-matter of claims 39 and 40 (agonists and antagonists). Consequently, preliminary examination has not been carried out for said claims (Rule 66.1(e) PCT). The International Preliminary Examining Authority (IPEA) agrees with the objection put forward by the International Searching Authority (ISA) as to insufficiency of disclosure concerning the subject-matter of claims 39 and 40 (Art. 5 PCT).
- 3 No examination of the claimed invention in respect of claims 25-27 can be carried out. A "transmembrane-domain deleted or inactivated variant" of "PRO285" (SEQ ID NO:1) is not disclosed in present application (Art. 5 PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/21141

- 4 Claim 37 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT (*in vivo* treatment or diagnostic methods on the human or animal body). Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of that claim (Art. 34(4)(a)(i) PCT).

For the assessment of the present claim 37 on the question whether they are industrially applicable, no unified criteria exist among the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but will allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

- 5 In summary, international preliminary examination has been restricted to the subject-matter of claims 5-8, 15 and partially claims 1, 2, 18-24, 28-30, 37, 38.

**Re ITEM V (Novelty, inventive step, industrial applicability)**

**1 Summary of the present application**

The present application is related to an isolated nucleic acid (SEQ ID NO:2) and a protein designated "PRO285" having the amino acid sequence of SEQ ID NO:1.

**3 Novelty (Art. 33(2) PCT)**

The subject-matter of claims 1, 2, 5-8, 15, 18-24, 28-30, 37 and 38 has not been made available to the public by any of the available prior art documents and can therefore be regarded as novel.



**3 Inventive step (Art. 33(3) PCT)**

- 3.1 Due to the important role of Toll proteins in the immune response there is a clear need in the art for the identification of human Toll genes/proteins that can be utilized in the development of therapeutics for disorders in the immune response (see e.g. **D1**, p. 396, last par.).
- 3.2 The closest prior art concerning claims 1, 2, 5-8, 15, 18-24, 28-30, 37 and 38 is **D1**. **D1** discloses the nucleic acid and peptide sequence of a human homologue of the *Drosophila* Toll protein. The gene of **D1** as well as the "PRO285" gene (SEQ ID NO:2) of present application were identified by using standard methods well known in the art: search for homologue sequences in EST database using *Drosophila* Toll sequences, isolation of the desired gene from a human cDNA library, e.g. brain, placenta ect. (see **D1**, p. 396, Methods and Example 1 of present application).
- 3.3 The presence of an inventive step cannot be acknowledged for the subject-matter of the examined claims as the skilled person would be prompted to use an already known nucleotide sequence of the *Drosophila* Toll gene or the human Toll gene disclosed in **D1** in a manner described in **D1** and thus arrive at the subject-matter of claims 1, 2, 5-8, 15, 18-24, 28-30, 37 and 38 without the exercise of inventive skill.

**4 Industrial applicability (Art. 33(4) PCT)**

Claims 1, 2, 5-8, 15, 18-24, 28-30 and 38 meet the criteria as set forth by Art. 33(4) PCT.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US98/21141

**R ITEM VI                      Certain published documents (Rule 70.10)**

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO-A-9850547	12.11.98	07.05.98	07.05.97

Said document has been published after the filing date of the present application and does therefore not constitute prior art in the meaning of Rule 64(1)(b) PCT. However, **D2** (WO-A-9850547) claims an earlier priority than the present application and will therefore become of relevance for the novelty of the claimed subject-matter during regional phase examination.

**Re ITEM VIII                      (Certain observations on the international application)**

- 1 The sequence of SEQ ID NO:2 corresponds to the *complete* sequence of Fig. 2 and not just the sequence "starting at nucleotide position 85 of Fig. 2". Claim 8 is therefore regarded as unclear (Art. 6 PCT).
- 2 The designations "PRO285" (claim 25) and "DNA 40021" (claim 28) could not be found in the available prior art documents. Therefore, "PRO285" and "DNA 40021" are regarded as an internal designation which do not provide a technical teaching to the skilled person. Claims referring to a product defined by said designation only therefore lack clarity (Art. 6 PCT). The appropriate SEQ ID NO or ATCC deposit No. is not given in claims 25 and 28, respectively. Any claim directly or indirectly depending on the unclear subject-matter of claims 25 and 28 does also not satisfy the requirements of Art. 6 PCT.

PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

TECH CENTER 1600/2900

Applicant's or agent's file reference

P1154R2

## FOR FURTHER ACTION

see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.

International application No.

PCT/US 98/21141

International filing date (day/month/year)

07/10/1998

(Earliest) Priority Date (day/month/year)

17/10/1997

Applicant

GENENTECH, INC. et al.

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☒ Unity of invention is lacking (see Box II).

4. With regard to the **title**,

the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.

1



None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/21141

## Box I Observations where certain claims were found unsatisfactory (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
See FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

See extra sheet, Invention 1.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

1. Claims: 5-8, 15, and partially claims 1, 2, 18-30, 37-40

Nucleic acid having sequence SEQ ID NO:1 encoding a PR0285 polypeptide and variants thereof, vector and host cell comprising the same and use thereof for producing a Toll polypeptide; Chimeric molecule comprising a PR0285 polypeptide; antibody binding a PR0285 polypeptide and use thereof for the treatment of septic shock; PR0285 agonists and antagonists

2. Claims: 9-11, 16, and partially claims 1, 2, 18-30, 37-40

Nucleic acid having sequence SEQ ID NO:3 encoding a PR0286 polypeptide and variants thereof, vector and host cell comprising the same and use thereof for producing a Toll polypeptide; Chimeric molecule comprising a PR0286 polypeptide; antibody binding a PR0286 polypeptide and use thereof for the treatment of septic shock; PR0286 agonists and antagonists

3. Claims: 3, 4, 12-14, 17, and partially claims 1, 18-30, 37-40

Nucleic acid having sequence SEQ ID NO:13 encoding a PR0358 polypeptide and variants thereof, vector and host cell comprising the same and use thereof for producing a Toll polypeptide; Chimeric molecule comprising a PR0358 polypeptide; antibody binding a PR0358 polypeptide and use thereof for the treatment of septic shock; PR0358 agonists and antagonists

4. Claims: 31-36, and partially 37, 38

Antibodies and variants of human hTLR2 receptor

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box (I), Item 1.

Although claim 38 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.

-----

Further defect(s) under Article 17(2)(a):

Continuation of Box (I), Item 2.

Claims Nos.: 40 41

Claims 40 and 41, relating to agonists and antagonists have not been searched due to the lack of adequate technical description thereof in the application.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 21141

## Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

The invention relates to the identification and isolation of DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/21141

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C12N15/81 C12N15/85 C12N5/10  
 C12N1/16 C07K19/00 C07K16/46 C07K16/28 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RUSLAN MEDZHITOV ET AL.: "A human homologue of the Drosophila Toll protein signals activation of adaptive immunity" NATURE, vol. 388, no. 6640, 24 July 1997 (1997-07-24), pages 394-397, XP002099039 LONDON GB cited in the application the whole document	1,2,5-8, 15, 18-30, 37,38
E	WO 98 50547 A (SCHERING CORPORATION) 12 November 1998 (1998-11-12) page 7, line 5 - page 25, line 2 page 37, line 20 - page 51, line 31	1,18-24, 38

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* & \* document member of the same patent family

Date of the actual completion of the international search

22 April 1999

Date of mailing of the international search report

21.07.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2200 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.



### Information on patent family members

PCT/US 98/21141

Form PCT/ISA/210 (patent family annex) (July 1992)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, C07K 14/705, C12N 15/81, 15/85, 5/10, 1/16, C07K 19/00, 16/46, 16/28, A61K 39/395</b>		A2	(11) International Publication Number: <b>WO 99/20756</b> (43) International Publication Date: 29 April 1999 (29.04.99)															
(21) International Application Number: <b>PCT/US98/21141</b> (22) International Filing Date: 7 October 1998 (07.10.98) (30) Priority Data: <table border="0"> <tr> <td>60/062,250</td> <td>17 October 1997 (17.10.97)</td> <td>US</td> </tr> <tr> <td>60/065,311</td> <td>13 November 1997 (13.11.97)</td> <td>US</td> </tr> <tr> <td>60/083,322</td> <td>28 April 1998 (28.04.98)</td> <td>US</td> </tr> <tr> <td>60/090,863</td> <td>26 June 1998 (26.06.98)</td> <td>US</td> </tr> <tr> <td>09/105,413</td> <td>26 June 1998 (26.06.98)</td> <td>US</td> </tr> </table>		60/062,250	17 October 1997 (17.10.97)	US	60/065,311	13 November 1997 (13.11.97)	US	60/083,322	28 April 1998 (28.04.98)	US	60/090,863	26 June 1998 (26.06.98)	US	09/105,413	26 June 1998 (26.06.98)	US	(74) Agents: DREGER, Ginger, R. et al.; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990 (US).  (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
60/062,250	17 October 1997 (17.10.97)	US																
60/065,311	13 November 1997 (13.11.97)	US																
60/083,322	28 April 1998 (28.04.98)	US																
60/090,863	26 June 1998 (26.06.98)	US																
09/105,413	26 June 1998 (26.06.98)	US																
(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GODDARD, Audrey [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). GODOWSKI, Paul, J. [US/US]; 2627 Easton Drive, Burlingame, CA 94010 (US). GURNEY, Austin, L. [US/US]; 1 Debbie Lane, Belmont, CA 94010 (US). MARK, Melanie, R. [US/US]; 958 B Chula Vista Avenue, Burlingame, CA 94010 (US). YANG, Ruey-Bing [CN/US]; 2045 Sea Cliff Way, San Bruno, CA 94066 (US).		Published Without international search report and to be republished upon receipt of that report.																

RECEIVED

AUG 11 1999

TECH CENTER 1600/2900

(54) Title: HUMAN TOLL HOMOLOGUES

><MW: 120922

MVFPMTLKRQILILFNIIILISKLLGARWFPKTLPCDVTLDVPKNHVIVDCTDKHLTEIP  
GGIPTNTTNLTTLTINHIPDISPASFHRDLHVEIDFRNCNCPVPIPLGSKNNMCIKRLQIKP  
RSFSGLTLYKSLYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYL  
QNCYYRNP CYVSYSIEKDAFLNLTKLKVLSLKDNNVTAVPTVLPSTLTELYLYNNMIAKI  
QEDDFNNLNQLQILDLSGNCPRCYNAPFPAPCKNNSPLQIPVNAFDALTELKVLRLHSN  
SLQHVPWRWFKNINKLQELDLSONFLAKEIGDAKFLHFLPSLIQLDLSFNFELQVYRASM  
NLSQAFSSLSKSLKILRIRGYVFKELKSFNLSPLHNLQNLVLDLGTNFIKIANLSMFKQF  
KRLKVIDLSVNKISPSGDSSEVGFCNSARTSVESYEPQVLEQLHYFRYDKYARSCRFKNK  
EASFMSVNESCYKYGQTLDSLKNSIFFVKSSDFQHLNFLKCLNLSGNLISQTLNGSEFQP  
LAELRYLDFSNNRLDLLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKV LQK  
LMMNDNDISSSTSRTMESESLRTELEFRGNHLDVLWREGDNRYLQLFKNLLKLEELD ISKN  
SLSFLPSGVFDGMPPNLKNLSLAKNGLKSFSWKKLQCLKNLETLDLSHNQLTTVPERLSN  
CSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKM LLL  
HHNRFLCTCDAVWFWVWNHTEVTIPYLATDVTCVGPAGHKGQSVISLDLYTCELDLTNL  
ILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK  
DPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLENLSQS IQLSKKTVFVMTDK  
YAKTENFKIAFYLSHQRLMDEKVDVILIFLEKPFQKSKFLQLRKRLCGSSVLEWPTNPQ  
AHPYFWQCLKNALATDNHVAYSQVFKETV

(57) Abstract

The invention relates to the identification and isolation of DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.

RECEIVED

AUG 11 1999

TECH CENTER 1600/2900

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## HUMAN TOLL HOMOLOGUES

### FIELD OF THE INVENTION

The present invention relates generally to the identification and isolation of novel DNAs designated herein as DNA40021, DNA42663 and DNA47361, and to the recombina-  
5 nt production of novel human Toll homologues (designated as PRO285, PRO286 and PRO358, respectively) encoded by said DNAs.

### BACKGROUND OF THE INVENTION

Membrane-bound proteins and receptors can play an important role in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesion molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.

Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interaction. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

Efforts are being undertaken by both industry and academia to identify new, native receptor proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor proteins.

The cloning of the Toll gene of *Drosophila*, a maternal effect gene that plays a central role in the establishment of the embryonic dorsal-ventral pattern, has been reported by Hashimoto *et al.*, Cell 52, 269-279 (1988). The *Drosophila* Toll gene encodes an integral membrane protein with an extracytoplasmic domain of 803 amino acids and a cytoplasmic domain of 269 amino acids. The extracytoplasmic domain has a potential membrane-spanning segment, and contains multiple copies of a leucine-rich segment, a structural motif found in many transmembrane proteins. The Toll protein controls dorsal-ventral patterning in *Drosophila* embryos and activates the transcription factor Dorsal upon binding to its ligand Spätzle. (Morisato and Anderson, Cell 76, 677-688 (1994).) In adult *Drosophila*, the Toll/Dorsal

signaling pathway participates in the anti-fungal immune response. (L naitre et al., Cell **86**, 973-983 (1996).)

A human homologue of the *Drosophila* Toll protein has been described by Medzhitov et al., Nature **388**, 394-397 (1997). This human Toll, just as *Drosophila* Toll, is a type I transmembrane protein, with an extracellular domain consisting of 21 tandemly repeated leucine-rich motifs (leucine-rich region - LRR), separated by a non-LRR region, and a cytoplasmic domain homologous to the cytoplasmic domain of the human interleukin-1 (IL-1) receptor. A constitutively active mutant of the human Toll transfected into human cell lines was shown to be able to induce the activation of NF- $\kappa$ B and the expression of NF- $\kappa$ B-controlled genes for the inflammatory cytokines IL-1, IL-6 and IL-8, as well as the expression of the constimulatory molecule B7.1, which is required for the activation of native T cells. It has been suggested that Toll functions in vertebrates as a non-clonal receptor of the immune system, which can induce signals for activating both an innate and an adaptive immune response in vertebrates. The human Toll gene reported by Medzhitov et al., *supra* was most strongly expressed in spleen and peripheral blood leukocytes (PBL), and the authors suggested that its expression in other tissues may be due to the presence of macrophages and dendritic cells, in which it could act as an early-warning system for infection. The public GenBank database contains the following Toll sequences: Toll1 (DNAX# HSU88540-1, which is identical with the random sequenced full-length cDNA #HUMRSC786-1); Toll2 (DNAX# HSU88878-1); Toll3 (DNAX# HSU88879-1); and Toll4 (DNAX# HSU88880-1, which is identical with the DNA sequence reported by Medzhitov et al., *supra*). A partial Toll sequence (Toll5) is available from GenBank under DNAX# HSU88881-1.

Further human homologues of the *Drosophila* Toll protein, designated as Toll-like receptors (huTLRs1-5) were recently cloned and shown to mirror the topographic structure of the *Drosophila* counterpart (Rock *et al.*, Proc. Natl. Acad. Sci. USA **95**, 588-593 [1998]). Overexpression of a constitutively active mutant of one human TLR (Toll-protein homologue - Medzhitov *et al.*, *supra*; TLR4 - Rock *et al.*, *supra*) leads to the activation of NF- $\kappa$ B and induction of the inflammatory cytokines and constimulatory molecules. Medzhitov *et al.*, *supra*.

#### SUMMARY OF THE INVENTION

Applicants have identified three novel cDNA clones that encode novel human Toll polypeptides, designated in the present application as PRO285 (encoded by DNA40021), PRO286 (encoded by DNA42663), and PRO358 (encoded by DNA47361).

In one embodiment, the invention provides an isolated nucleic acid molecule comprising a DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO285 polypeptide having amino acid residues 27 to 839 of Fig. 1 (SEQ ID NO:1); or (b) to a DNA molecule encoding a PRO286 polypeptide having amino acid residues 27 to 825 of Fig. 3 (SEQ ID NO:3), or (c) to a DNA molecule encoding a PRO358 polypeptide having amino acids

20 to 575 of Fig. 12A-B (SEQ ID NO: 13), or (d) the complement of the DNA molecule of (a), (b), or (c). The complementary DNA molecule preferably remains stably bound to such encoding nucleic acid sequence under at least moderate, and optionally, under high stringency conditions.

5 In a further embodiment, the isolated nucleic acid molecule comprises a polynucleotide that has at least about 90%, preferably at least about 95% sequence identity with a polynucleotide encoding a polypeptide comprising the sequence of amino acids 1 to 839 of Fig. 1 (SEQ ID NO:1); or at least about 90%, preferably at least about 95% sequence identity with a polynucleotide encoding a polypeptide comprising the sequence of amino acids 1 to 1041 of Fig. 3 (SEQ ID NO: 3); or at least about 90%, preferably at least about 95% sequence identity with  
10 a polynucleotide encoding a polypeptide comprising the sequence of amino acids 1 to 811 of Fig. 12A-B (SEQ ID NO: 13).

In a specific embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding native or variant PRO285, PRO286, and PRO358 polypeptides, with or without the N-terminal signal sequence, and with or without the  
15 transmembrane regions of the respective full-length sequences. In one aspect, the isolated nucleic acid comprises DNA encoding a mature, full-length native PRO285, PRO286, or PRO358 polypeptide having amino acid residues 1 to 1049 of Fig. 1 (SEQ ID NO: 1), 1 to 1041 of Fig. 3 (SEQ ID NO: 3), and 1 to 811 of Fig. 12A-B (SEQ ID NO: 13), or is complementary to such encoding nucleic acid sequence. In another aspect, the invention concerns an isolated nucleic  
20 acid molecule that comprises DNA encoding a native PRO285, PRO286, or PRO358 polypeptide without an N-terminal signal sequence, or is complementary to such encoding nucleic acid sequence. In yet another embodiment, the invention concerns nucleic acid encoding transmembrane-domain deleted or inactivated forms of the full-length native PRO285, PRO286 and PRO358 proteins.

25 In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PRO285, PRO286 or PRO358 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 85 and about 3283 inclusive, of Figure 2 (SEQ ID NO: 2), or to the complement of the nucleic acid between about residues 57 and about 4199, inclusive, of Figure 4 (SEQ ID NO: 4), or to the complement of the nucleic acid between  
30 about residues 111 and about 2544 of Figures 13A-B (SEQ ID NO: 14). Preferably, hybridization occurs under stringent hybridization and wash conditions.

In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least  
35 about 95% positives when compared with the amino acid sequence of residues 1 to 1049, inclusive of Figure 1 (SEQ ID NO:1), or amino acid residues 1 to 1041, inclusive of Figure 3 (SEQ ID NO: 3), or amino acid residues 1 to 811, inclusive of Figures 12A-B (SEQ ID NO: 13, or (b) the complement of a DNA of (a).

In another embodiment, the invention the isolated nucleic acid molecule comprises the clone (DNA 40021-1154) deposited on October 17, 1997, under ATCC number 209389; or the clone (DNA 42663-1154) deposited on October 17, 1997, under ATCC number 209386; or the clone (DNA 47361-1249) deposited on November 7, 1997, under ATCC number 209431.

In yet another embodiment, the invention provides a vector comprising DNA encoding PRO285, PRO286 and PRO358 polypeptides, or their variants. Thus, the vector may comprise any of the isolated nucleic acid molecules hereinabove defined.

In a specific embodiment, the invention provides a vector comprising a polynucleotide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity with a polynucleotide encoding a polypeptide comprising the sequence of amino acids 20 to 811 of Fig. 12A-B (SEQ ID NO:13), or the complement of such polynucleotide. In a particular embodiment, the vector comprises DNA encoding the novel Toll homologue (PRO358), with or without the N-terminal signal sequence (about amino acids 1 to 19), or a transmembrane-domain (about amino acids 576-595) deleted or inactivated variant thereof, or the extracellular domain (about amino acids 20 to 595) of the mature protein, or a protein comprising any one of these sequences. A host cell comprising such a vector is also provided. A similar embodiment will be apparent for vectors comprising polynucleotides encoding the PRO285 and PRO286 Toll homologues, with or without the respective signal sequences and/or transmembrane-domain deleted or inactivated variants thereof, and specifically, vectors comprising the extracellular domains of the mature PRO285 and PRO286 Toll homologues, respectively.

A host cell comprising such a vector is also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast.

A process for producing PRO285, PRO286 and PRO358 polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of PRO285, PRO286, and PRO358, respectively, and recovering PRO285, PRO286, or PRO358 from the cell culture.

In another embodiment, the invention provides isolated PRO285, PRO286 and PRO358 polypeptides. In particular, the invention provides isolated native sequence PRO285 and PRO286 polypeptides, which in one embodiment, include the amino acid sequences comprising residues 1 to 1049 and 1 to 1041 of Figures 1 and 3 (SEQ ID NOs:1 and 3), respectively. The invention also provides for variants of the PRO285 and PRO286 polypeptides which are encoded by any of the isolated nucleic acid molecules hereinabove defined. Specific variants include, but are not limited to, deletion (truncated) variants of the full-length native sequence PRO285 and PRO286 polypeptides which lack the respective N-terminal signal sequences and/or have their respective transmembrane and/or cytoplasmic domains deleted or inactivated. The invention further provides an isolated native sequence PRO358 polypeptide,

or variants thereof. In particular, the invention provides an isolated native sequence PRO358 polypeptide, which in certain embodiments, includes the amino acid sequence comprising residues 20 to 575, or 20 to 811, or 1 to 811 of Figures 12A-B (SEQ ID NO: 13).

In a further aspect, the invention concerns an isolated PRO285, PRO286 or PRO358 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of amino acid residues 1 to 1049, inclusive of Figure 1 (SEQ ID NO:1), or amino acid residues 1 to 1041, inclusive of Figure 3 (SEQ ID NO: 3), or amino acid residues 1 to 811, inclusive of Figures 12A-B (SEQ ID NO: 13).

In a still further aspect, the invention provides a polypeptide produced by (I) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO285, PRO286 or PRO358 polypeptide having the sequence of amino acid residues from about 1 to about 1049, inclusive of Figure 1 (SEQ ID NO:1), or amino acid residues from about 1 to about 1041, inclusive of Figure 3 (SEQ ID NO: 3), or amino acid residues from about 1 to about 811, inclusive of Figures 12A-B (SEQ ID NO: 13), or (b) the complement of a DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

In another embodiment, the invention provides chimeric molecules comprising PRO285, PRO286, or PRO358 polypeptides fused to a heterologous polypeptide or amino acid sequence. An example of such a chimeric molecule comprises a PRO285, PRO286, or PRO358 polypeptide fused to an epitope tag sequence or a Fc region of an immunoglobulin. An example of such a chimeric molecule comprises a PRO358 polypeptide (including its signal peptide and/or transmembrane-domain and, optionally, intracellular domain, deleted variants), fused to an epitope tag sequence or a Fc region of an immunoglobulin. In a preferred embodiment, the fusion contains the extracellular domain of PRO358 fused to an immunoglobulin constant region, comprising at least the CH2 and CH3 domains. Similar specific embodiments exist and are disclosed herein for chimeric molecules comprising a PRO285 or PRO286 polypeptide.

In another embodiment, the invention provides an antibody which specifically binds to PRO285, PRO286 or PRO358 polypeptides. Optionally, the antibody is a monoclonal antibody. The invention specifically includes antibodies with dual specificities, e.g., bispecific antibodies binding more than one Toll polypeptide.

In yet another embodiment, the invention concerns agonists and antagonists of the native PRO285, PRO286 and PRO358 polypeptides. In a particular embodiment, the agonist or antagonist is an anti-PRO285, anti-PRO286 or anti-PRO358 antibody.



In a further embodiment, the invention concerns screening assays to identify agonists or antagonists of the native PRO285, PRO286 and PRO358 polypeptides.

In a still further embodiment, the invention concerns a composition comprising a PRO285, PRO286 or PRO358 polypeptide, or an agonist or antagonist as hereinabove defined,  
5 in combination with a pharmaceutically acceptable carrier.

The invention further concerns a composition comprising an antibody specifically binding a PRO285, PRO286 or PRO358 polypeptide, in combination with a pharmaceutically acceptable carrier.

The invention also concerns a method of treating septic shock comprising  
10 administering to a patient an effective amount of an antagonist of a PRO285, PRO286 or PRO358 polypeptide. In a specific embodiment, the antagonist is a blocking antibody specifically binding a native PRO285, PRO286 or PRO358 polypeptide.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the derived amino acid sequence of a native sequence human Toll  
15 protein, designated PRO285 (SEQ ID NO: 1).

Figure 2 shows the nucleotide sequence of a native sequence human Toll protein cDNA designated DNA40021 (SEQ ID NO: 2), which encodes PRO285.

Figure 3 shows the derived amino acid sequence of a native sequence human Toll protein, designated PRO286 (SEQ ID NO: 3).

Figure 4 shows the nucleotide sequence of a native sequence human Toll protein cDNA designated DNA42663 (SEQ ID NO: 4), which encodes PRO 286.  
20

Figure 5 shows the expression pattern of human Toll receptor 2 (huTLR2) (Rock *et al.*, *supra*). a. Northern analysis of human multiple immune tissues probed with a TLR2 probe. PBL, peripheral blood leukocytes. b. Enriched expression of TLR2 in macrophages, and  
25 transcriptional up-regulation of TLR2 in response to LPS. Quantitative RT-PCR was used to determine the relative expression levels of TLR2 in PBL, T cells, macrophages (MΦ), and LPS-stimulated macrophages (MΦ+LPS).

Figure 6 TLR2 mediates LPS-induced signaling. a. 293 cells stably expressing TLR2 acquire LPS responsiveness. Either a population of stable clones expressing gD.TLR2  
30 (293-TLR2 pop1) or a single clone of cells expressing gD.TLR2 (293-TLR2 clone 1) or control cells (293-MSCV) that were stably transfected with the expression vector alone were transiently transfected with pGL3.ELAM.tk and then stimulated with 1 µg/ml of 055:B5 enhancer for 6 h with or without LBP in serum-free medium. Activation of the ELAM enhancer was measured as described in the Examples. Results were obtained from two independent experiments. No  
35 stimulation was observed using the control reporter plasmid that lacked the ELAM enhancer (data not shown). Expression of the reporter plasmid was equivalent in untreated cells or cells treated with LBP alone (data not shown). b. Western blot showing expression of epitope-tagged TLR2 in 293 cells. c. Time course of TLR2-dependent LPS-induced activation and translocation of NF-κB. Nuclear extracts were prepared from cells treated with 055:B5 LPS (10 µg/ml) and

LBP for the indicated times (top), or cells pretreated with 1  $\mu$ M cycloheximide (CHX) for 1h the stimulated with 1  $\mu$ g/ml LPS for 1h in the presence of LBP in serum-free medium (bottom). d. Effect of mCD14 on NF- $\kappa$ B activation by TLR2. Vector control (193-MSCV) or 293-TLR2 pop1 cells were transfected with the reporter plasmid, and a CD14 expression vector (+mCD14) or vector control (-mCD14), respectively. After 24h, transfected cells were stimulated with 055:B5 LPS for 6h in the presence of LBP in serum-free medium. The data presented are representative from three independent experiments.

Figure 7 Domain function of TLR2 in signaling. a. Illustrations of various TLR2 constructs. TLR2-WT, the full-length epitope-tagged form of TLR2, TLR2- $\Delta$ 1 and - $\Delta$ 2 represent a truncation of 13 or 141 amino acids at the carboxyl terminus, respectively. CD4-TLR2, a human CD4-TLR2 chimera replacing the extracellular domain of TLR2 with amino acids 1-205 of human CD4. ECD, extracellular domain; TM, transmembrane region; ICD, intracellular domain. b. C-terminal residues critical for IL-1R and TLR2 signal transduction. Residue numbers are shown to the right of each protein. Arrow indicated the position of the TLR2- $\Delta$ 1 truncation. \*, residues essential for IL-1R signaling (Heguy *et al.*, *J. Biol. Chem.* 267, 2605-2609 [1992]; Croston *et al.*, *J. Biol. Chem.* 270, 16514-16517 [1995]) I, identical amino acid; :, conservative changes. c. TLR-R2 variants fail to induce NF- $\kappa$ B in response to LPS and LBP. 293 cells were transiently transfected with pGL3.ELAM.tk and expression vectors encoding full-length TLR2 or TLR2 variants as indicated. The cells were also transfected with a CD14 expression plasmid (+mCD14) or with a control plasmid (-mCD14). Equal expression of each protein is confirmed by Western blot using either anti-gD or CD4 antibody (bottom). The luciferase assay was performed as described in the Examples. Data were obtained from duplicate experiments.

Figure 8 High potency of *E coli* K12 LPS (LCD25) and its binding to TLR2. a. Dose-response curve of various LPS preparations. b. Specific interaction of [ $^3$ H]-LPS (LCD25) with the extracellular domain of TLR2. Specific binding was observed to TLR2-Fc, but not to either Fc alone, or fusion proteins containing the extracellular domains of Rse, Axl, Her2, or Her4. Binding to TLR2-Fc was specifically competed with LCD25 LPS, but not with detoxified LPS.

Figure 9 TLR2 is required for the LPS-induced IL-8 expression. 293-MSCV vector control and 293-TLR2 cells transiently expressing mCD14 were stimulated with LBP alone or together with the indicated type of LPS at concentrations of 1 $\mu$ g/ml in serum-free medium for 6h. Equal amounts of poly-(A) RNAs were used for Northern analysis.

Figure 10 Nucleotide sequence encoding huTLR2 (SEQ ID NO:11).

Figure 11 Amino acid sequence of huTLR2 (SEQ ID NO:12).

Figures 12A-B show the derived amino acid sequence of a native sequence human Toll protein, designated PRO358 (SEQ ID NO: 13). In the Figure, amino acids 1 through 19 form a putative signal sequence, amino acids 20 through 575 are the putative extracellular domain, with amino acids 20 through 54 having the characteristics of leucine rich repeats,

amino acids 576 through 595 are a putative transmembrane domain, whereas amino acids 596 through 811 form an intracellular domain.

Figures 13A-B (SEQ ID NO: 14) show the nucleotide sequence of a native sequence human Toll protein cDNA designated DNA47361, which encodes the mature, full-length Toll protein, PRO358. As the sequence shown contains some extraneous sequences, the ATG start codon is underlined, and the TAA stop codon is boxed.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### I. Definitions

The terms "PRO285 polypeptide", "PRO286 polypeptide", "PRO285" and "PRO286", when used herein, encompass the native sequence PRO285 and PRO286 Toll proteins and variants (which are further defined herein). The PRO285 and PRO286 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

A "native sequence PRO285" or "native sequence PRO286" comprises a polypeptide having the same amino acid sequence as PRO285 or PRO286 derived from nature. Such native sequence Toll polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The terms "native sequence PRO285" and "native sequence PRO286" specifically encompass naturally-occurring truncated or secreted forms of the PRO285 and PRO286 polypeptides disclosed herein (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the PRO285 and PRO286 polypeptides. In one embodiment of the invention, the native sequence PRO285 is a mature or full-length native sequence PRO285 polypeptide comprising amino acids 1 to 1049 of Fig. 1 (SEQ ID NO: 1), while native sequence PRO286 is a mature or full-length native sequence PRO286 polypeptide comprising amino acids 1 to 1041 of Fig. 3 (SEQ ID NO:3). In a further embodiment, the native sequence PRO285 comprises amino acids 27-1049, or 27-836 of Fig. 1 (SEQ ID NO:1), or amino acids 27-1041, or 27-825 of Fig. 3 (SEQ ID NO:3).

The terms "PRO285 variant" and "PRO286 variant" mean an active PRO285 or PRO286 polypeptide as defined below having at least about 80% amino acid sequence identity with PRO285 having the deduced amino acid sequence shown in Fig. 1 (SEQ ID NO:1) for a full-length native sequence PRO285, or at least about 80% amino acid sequence identity with PRO286 having the deduced amino acid sequence shown in Fig. 3 (SEQ ID NO:3) for a full-length native sequence PRO286. Such variants include, for instance, PRO285 and PRO286 polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the sequences of Figs.1 and 3 (SEQ ID NO: 1 and 3), respectively. Ordinarily, a PRO285 or PRO286 variant will have at least about 80% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, and even more preferably at least about 95% amino acid sequence identity with the amino acid sequence of Fig. 1 or Fig. 3 (SEQ

ID NOs:1 and 3). Preferred variants are those which show a high degree of sequence identity with the extracellular domain of a native sequence PRO285 or PRO286 polypeptide. In a special embodiment, the PRO285 and PRO286 variants of the present invention retain at least a C-terminal portion of the intracellular domain of the corresponding native proteins, and most preferably they retain most of the intracellular and the extracellular domains. However, depending on their intended use, such variants may have various amino acid alterations, e.g., substitutions, deletions and/or insertions within these regions.

The terms "PRO358 polypeptide", "PRO358", "PRO358 Toll homologue" and grammatical variants thereof, as used herein, encompass the native sequence PRO358 Toll protein and variants (which are further defined herein). The PRO358 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

A "native sequence PRO358" comprises a polypeptide having the same amino acid sequence as PRO358 derived from nature. Such native sequence Toll polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO358" specifically encompasses naturally-occurring truncated or secreted forms of the PRO358 polypeptide disclosed herein (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants. In one embodiment of the invention, the native sequence PRO358 is a mature or full-length native sequence PRO358 polypeptide comprising amino acids 20 to 811 of Fig. 12A-B (SEQ ID NO: 13), with or without the N-terminal signal sequence (amino acids 1 to 19), and with or without the N-terminal methionine. In another embodiment, the native sequence PRO358 is the soluble form of the full-length PRO358, retaining the extracellular domain of the full-length protein (amino acids 29 to 575), with or without the N-terminal signal sequence, and with or without the N-terminal methionine.

The term "PRO358 variant" means an active PRO358 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with PRO358 having the deduced amino acid sequence shown in Fig. 12A-B (SEQ ID NO:13). Such variants include, for instance, PRO358 polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the sequences of Fig. 12A-B (SEQ ID NO:13). Variants specifically include transmembrane-domain deleted and inactivated variants of native sequence PRO358, which may also have part or whole of their intracellular domain deleted. Preferred variants are those which show a high degree of sequence identity with the extracellular domain of the native sequence PRO358 polypeptide. In a special embodiment, the PRO 358 variants of the present invention retain at least a C-terminal portion of the intracellular domain of a corresponding native protein, and most preferably they retain most of the intracellular and the extracellular

domains. However, depending on their intended use, such variants may have various amino acid alterations, e.g., substitutions, deletions and/or insertions within these regions.

"Percent (%) amino acid sequence identity" with respect to the PRO285, PRO286 and PRO358 sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the PRO285, PRO286, or PRO358 sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. The ALIGN software is preferred to determine amino acid sequence identity.

In a specific aspect, "percent (%) amino acid sequence identity" with respect to the PRO285, PRO286 and PRO358 sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the PRO285, PRO286 and PRO358 sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. The % identity values used herein are generated by WU-BLAST-2 which was obtained from [Altschul et al., Methods in Enzymology, 266: 460-480 (1996); <http://blast.wustl.edu/blast/README.html>]. WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span =1, overlap fraction = 0.125, word threshold (T) = 11. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity. A % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region. The "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).

The term "positives", in the context of sequence comparison performed as described above, includes residues in the sequences compared that are not identical but have similar properties (e.g. as a result of conservative substitutions). The % value of positives is determined by the fraction of residues scoring a positive value in the BLOSUM 62 matrix divided by the total number of residues in the longer sequence, as defined above.

"Percent (%) nucleic acid sequence identity" with respect to the DNA40021, DNA42663 and DNA47361 sequences identified herein is defined as the percentage of

nucleotides in a candidate sequence that are identical with the nucleotides in the DNA40021, DNA42663 and DNA47361 sequences, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. The ALIGN software is preferred to determine nucleic acid sequence identity.

Specifically, "percent (%) nucleic acid sequence identity" with respect to the coding sequence of the PRO285, PRO286 and PRO358 polypeptides identified herein is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues in the PRO285, PRO286 and PRO358 coding sequence. The identity values used herein were generated by the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the PRO285, PRO286, or PRO358 natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" DNA40021, DNA42663 or DNA47361 nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the DNA40021, DNA42663 or DNA47361 nucleic acid. An isolated DNA40021, DNA42663 or DNA47361 nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated DNA40021, DNA42663 and DNA47361 nucleic acid molecules therefore are distinguished from the DNA40021, DNA42663 or DNA47361 nucleic acid molecule as it exists in natural cells. However, an isolated DNA40021, DNA42663 or DNA47361 nucleic acid molecule includes DNA40021, DNA42663 and DNA47361 nucleic acid molecules contained in cells that ordinarily express DNA40021, DNA42663 or DNA47361 where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

"Toll receptor2", "TLR2" and "huTLR2" are used interchangeably, and refer to a human Toll receptor designated as "HuTLR2" by Rock *et al.*, Proc. Natl. Acad. Sci. USA 95, 588-593 (1998). The nucleotide and amino acid sequences of huTLR2 are shown in Figures 10 (SEQ ID NO: 11) and 11 (SEQ ID NO: 12), respectively.

5 The term "expression vector" is used to define a vector, in which a nucleic acid encoding a Toll homologue protein herein is operably linked to control sequences capable of affecting its expression in suitable host cells. Vectors ordinarily carry a replication site (although this is not necessary where chromosomal integration will occur). Expression vectors also include marker sequences which are capable of providing phenotypic selection in  
10 transformed cells. For example, *E. coli* is typically transformed using pBR322, a plasmid derived from an *E. coli* species (Bolivar, *et al.*, Gene 2: 95 [1977]). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells, whether for purposes of cloning or expression. Expression vectors also optimally will contain sequences which are useful for the control of transcription and translation, e.g.,  
15 promoters and Shine-Dalgarno sequences (for prokaryotes) or promoters and enhancers (for mammalian cells). The promoters may be, but need not be, inducible; even powerful constitutive promoters such as the CMV promoter for mammalian hosts have been found to produce the LHR without host cell toxicity. While it is conceivable that expression vectors need not contain any expression control, replicative sequences or selection genes, their absence may hamper the  
20 identification of hybrid transformants and the achievement of high level hybrid immunoglobulin expression.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an  
25 operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates  
30 in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be  
35 contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term "antibody" is used in the broadest sense and specifically covers single anti-PRO285, anti-PRO286 and anti-PRO358 monoclonal antibodies (including agonist,

antagonist, and neutralizing antibodies) and anti-PRO285, anti-PRO286 and anti-PRO358 antibody compositions with polyepitopic specificity. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, prevents, inhibits, or neutralizes a biological activity of a native Toll receptor disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics, or enhances a biological activity of a native Toll receptor disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native Toll receptor polypeptides, peptides, small organic molecules, etc.

"Active" or "activity" for the purposes herein refers to form(s) of PRO285, PRO286 and PRO358 which retain the biologic and/or immunologic activities of native or naturally-occurring PRO285, PRO286 and PRO358, respectively. A preferred "activity" is the ability to induce the activation of NF- $\kappa$ B and/or the expression of NF- $\kappa$ B-controlled genes for the inflammatory cytokines IL-1, IL-6 and IL-8. Another preferred "activity" is the ability to activate an innate and/or adaptive immune response in vertebrates. A further preferred "activity" is the ability to sense the presence of conserved molecular structures present on microbes, and specifically the ability to mediate lipopolysaccharide (LPS) signaling. The same "activity" definition applies to agonists (e.g. agonist antibodies) of PRO285, PRO286 and PRO358 polypeptides. As noted above, the "activity" an antagonist (including agonist antibodies) of a PRO285, PRO286 or PRO358 polypeptide is defined as the ability to counteract, e.g. partially or fully block, prevent, inhibit, or neutralize any of the above-identified activities of a PRO285, PRO286 or PRO358 polypeptide.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel *et al.*, Current Protocols in Molecular Biology (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C;



(2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a FIZZ polypeptide fused to a "tag polypeptide." The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and the immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the

disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

“Chronic” administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time.

“Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cows, horses, sheep, pigs, etc. Preferably, the mammal is human.

Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

The term “lipopolysaccharide” or “LPS” is used herein as a synonym of “endotoxin.” Lipopolysaccharides (LPS) are characteristic components of the outer membrane of Gram-negative bacteria, e.g., *Escherichia coli*. They consist of a polysaccharide part and a fat called lipid A. The polysaccharide, which varies from one bacterial species to another, is made up of the O-specific chain (built from repeating units of three to eight sugars) and the two-part core. Lipid A virtually always includes two glucosamine sugars modified by phosphate and a variable number of fatty acids. For further information see, for example, Rietschel and Brade, Scientific American August 1992, 54-61.

The term “septic shock” is used herein in the broadest sense, including all definitions disclosed in Bone, Ann. Intern. Med. 114, 332-333 (1991). Specifically, septic shock starts with a systemic response to infection, a syndrome called sepsis. When this syndrome results in hypotension and organ dysfunction, it is called septic shock. Septic shock may be initiated by gram-positive organisms and fungi, as well as endotoxin-containing Gram-negative organisms. Accordingly, the present definition is not limited to “endotoxin shock.”

## II. Compositions and Methods of the Invention

### A. Full-length PRO285, PRO286 and PRO358

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO285 and PRO286. In particular, Applicants have identified and isolated cDNAs encoding PRO285 and PRO286 polypeptides, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that the coding sequences of PRO285 and PRO286 are highly homologous to DNA sequences HSU88540\_1, HSU88878\_1, HSU88879\_1, HSU88880\_1, and HSU88881\_1 in the GenBank database.

The present invention further provides newly identified and isolated nucleotide sequences encoding a polypeptide referred to in the present application as PRO358. In particular, Applicants have identified and isolated cDNA encoding a novel human Toll polypeptide (PRO358), as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that the coding sequence of PRO358 shows significant homology to DNA sequences HSU88540\_1, HSU88878\_1, HSU88879

\_1, HSU88880\_1, HS88881\_1, and HSU79260\_1 in the GenBank database. With the exception of HSU79260\_1, the noted proteins have been identified as human toll-like receptors.

Accordingly, it is presently believed that the PRO285, PRO286 and PRO358 proteins disclosed in the present application are newly identified human homologues of the *Drosophila* protein Toll, and are likely to play an important role in adaptive immunity. More specifically, PRO285, PRO286 and PRO358 may be involved in inflammation, septic shock, and response to pathogens, and play possible roles in diverse medical conditions that are aggravated by immune response, such as, for example, diabetes, ALS, cancer, rheumatoid arthritis, and ulcers. The role of PRO285, PRO286 and PRO358 as pathogen pattern recognition receptors, sensing the presence of conserved molecular structures present on microbes, is further supported by the data disclosed in the present application, showing that a known human Toll-like receptor, TLR2 is a direct mediator of LPS signaling.

#### B. PRO 285, PRO286 and PRO358 Variants

In addition to the full-length native sequence PRO285, PRO286 and PRO358 described herein, it is contemplated that variants of these sequences can be prepared. PRO285, PRO286 and PRO358 variants can be prepared by introducing appropriate nucleotide changes into the PRO285, PRO286 or PRO358 DNA, or by synthesis of the desired variant polypeptides. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO285, PRO286 or PRO358 polypeptides, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the native full-length sequence PRO285, PRO286 or PRO358, or in various domains of the PRO285, PRO286, or PRO358 described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO285, PRO286, or PRO358 polypeptide that results in a change in the amino acid sequence as compared with the corresponding native sequence polypeptides. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO285, PRO286, or PRO358. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO285, PRO286, or PRO358 with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity in the *in vitro* assay described in the Examples below.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO285 or PRO286 variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

Variants of the PRO285, PRO286 and PRO358 Toll proteins disclosed herein include proteins in which the transmembrane domains have been deleted or inactivated. Transmembrane regions are highly hydrophobic or lipophilic domains that are the proper size to span the lipid bilayer of the cellular membrane. They are believed to anchor the native, mature PRO285, PRO286 and PRO358 polypeptides in the cell membrane. In PRO285 the transmembrane domain stretches from about amino acid position 840 to about amino acid position 864. In PRO286 the transmembrane domain is between about amino acid position 826 and about amino acid position 848. In PRO 358 the transmembrane domain is between about amino acid position 576 and amino acid position 595.

Deletion or substitution of the transmembrane domain will facilitate recovery and provide a soluble form of a PRO285, PRO286, and PRO358 polypeptide by reducing its cellular or membrane lipid affinity and improving its water solubility. If the transmembrane and cytoplasmic domains are deleted one avoids the introduction of potentially immunogenic epitopes, either by exposure of otherwise intracellular polypeptides that might be recognized by the body as foreign or by insertion of heterologous polypeptides that are potentially immunogenic. A principal advantage of a transmembrane domain deleted PRO285, PRO286 or PRO358 is that it is secreted into the culture medium of recombinant hosts. This variant is soluble in body fluids such as blood and does not have an appreciable affinity for cell membrane lipids, thus considerably simplifying its recovery from recombinant cell culture.

It will be amply apparent from the foregoing discussion that substitutions, deletions, insertions or any combination thereof are introduced to arrive at a final construct. As a general proposition, soluble variants will not have a functional transmembrane domain and preferably will not have a functional cytoplasmic sequence. This is generally accomplished by

deletion of the relevant domain, although adequate insertional or substitutional variants also are effective for this purpose. For example, the transmembrane domain is substituted by any amino acid sequence, e.g. a random or predetermined sequence of about 5 to 50 serine, threonine, lysine, arginine, glutamine, aspartic acid and like hydrophilic residues, which altogether exhibit a hydrophilic hydropathy profile. Like the deletional (truncated) PRO285, PRO286 and PRO358 variants, these variants are secreted into the culture medium of recombinant hosts.

Further deletional variants of the full-length mature PRO285, PRO286, and PRO358 polypeptides (or transmembrane domain deleted to inactivated forms thereof) include variants from which the N-terminal signal peptide (putatively identified as amino acids 1 to 19 for PRO285 and PRO286, and as amino acids 1 to 26 for PRO358) and/or the initiating methionine has been deleted. The native signal sequence may also be substituted by another (heterologous) signal peptide, which may be that of another Toll-like protein, or another human or non-human (e.g., bacterial, yeast or non-human mammalian) signal sequence.

It is believed that the intracellular domain, and especially its C-terminal portion, is important for the biological function of these polypeptides. Accordingly, if the objective is to make variants which retain the biological activity of a corresponding native Toll-like protein, at least a substantial portion of these regions is retained, or the alterations, if any, involve conservative amino acid substitutions and/or insertions or amino acids which are similar in character to those present in the region where the amino acid is inserted. If, however, a substantial modification of the biological function of a native Toll receptor is required (e.g., the objective is to prepare antagonists of the respective native Toll polypeptides), the alterations involve the substitution and/or insertion of amino acids, which differ in character from the amino acid at the targeted position in the corresponding native Toll polypeptide.

Naturally-occurring amino acids are divided into groups based on common side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophobic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Conservative substitutions involve exchanging a member within one group for another member within the same group, whereas non-conservative substitutions will entail exchanging a member of one of these classes for another. Variants obtained by non-conservative substitutions are expected to result in more significant changes in the biological properties/function of the obtained variant.

Amino acid insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as

intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e. insertions within the PRO285, PRO286 or PRO358 protein amino acid sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5 residues, more preferably 1 to 3 residues. Examples of terminal insertions include the PRO285, PRO286 and PRO358 polypeptides with an N-terminal methionyl residue, an artifact of its direct expression in bacterial recombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the PRO285, PRO286, or PRO358 molecule to facilitate the secretion of the mature I-TRAF proteins from recombinant host cells. Such signal sequences will generally be obtained from, and thus homologous to, the intended host cell species. Suitable sequences include STII or Ipp for E. coli, alpha factor for yeast, and viral signals such as herpes gD for mammalian cells.

Other insertional variants of the native Toll-like molecules disclosed herein include the fusion of the N- or C-terminus of the native sequence molecule to immunogenic polypeptides, e.g. bacterial polypeptides such as beta-lactamase or an enzyme encoded by the E. coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin regions (preferably immunoglobulin constant regions to yield immunoadhesins), albumin, or ferritin, as described in WO 89/02922 published on 6 April 1989. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

Since it is often difficult to predict in advance the characteristics of a variant Toll-like protein, it will be appreciated that screening will be needed to select the optimum variant. For this purpose biochemical or other screening assays, such as those described hereinbelow, will be readily available.

#### C. Modifications of the PRO285, PRO286 and PRO358 Toll Proteins

Covalent modifications of the PRO285, PRO286 and PRO358 human Toll homologues are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of the PRO285, PRO286 or PRO358 protein with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues. Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO285, PRO286, or PRO358 to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO285 -PRO286, or -PRO358 antibodies, and vice-versa.

Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis-(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as m thyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutamyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -

amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Derivatization with bifunctional agents is useful for preparing intramolecular aggregates of the Toll-like receptors herein with polypeptides as well as for cross-linking these polypeptides to a water insoluble support matrix or surface for use in assays or affinity purification. In addition, a study of interchain cross-links will provide direct information on conformational structure. Commonly used cross-linking agents include 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, homobifunctional imidoesters, and bifunctional maleimides. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatable intermediates which are capable of forming cross-links in the presence of light. Alternatively, reactive water insoluble matrices such as cyanogen bromide activated carbohydrates and the systems reactive substrates described in U.S. Patent Nos. 3,959,642; 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; 4,055,635; and 4,330,440 are employed for protein immobilization and cross-linking.

Another type of covalent modification of the PRO285, PRO286 and PRO358 polypeptides included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means) and/or adding one or more glycosylation sites that are not present in the native sequence. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the carbohydrates present.

The native, full-length PRO285 (encoded by DNA 40021) has potential N-linked glycosylation sites at the following amino acid positions: 66, 69, 167, 202, 215, 361, 413, 488, 523, 534, 590, 679, 720, 799 and 942. The native, full-length PRO286 (encoded by DNA42663) has potential N-linked glycosylation sites at the following amino acid positions: 29, 42, 80, 88, 115, 160, 247, 285, 293, 358, 362, 395, 416, 443, 511, 546, 582, 590, 640, 680, 752, 937 and 1026.

Addition of glycosylation sites to the PRO285, PRO286 and PRO358 polypeptides may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence (for O-linked glycosylation sites). The amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO285, PRO286, and PRO358 polypeptides at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO285, PRO286 and PRO358 polypeptides is by chemical or enzymatic coupling of glycosides

to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the PRO285, PRO286 and PRO358 polypeptides may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification comprises linking the PRO285, PRO286 and PRO358 polypeptides to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The PRO285, PRO286 and PRO358 polypeptides of the present invention may also be modified in a way to form a chimeric molecule comprising PRO285, PRO286, PRO358, or a fragment thereof, fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of the PRO285, PRO286 or PRO358 polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of a native or variant PRO285, PRO286, or PRO358 molecule. The presence of such epitope-tagged forms can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO285, PRO286, or PRO358 polypeptides to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

In a further embodiment, the chimeric molecule may comprise a fusion of the PRO285, PRO286 or PRO358 polypeptides, or fragments thereof, with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an Ig, such as, IgG molecule. The Ig fusions preferably



include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO285, PRO286, or PRO358 polypeptide in place of at least one variable region within an Ig molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

5                   D. Preparation of PRO285, PRO286 and PRO358 polypeptides

The description below relates primarily to production of PRO285, PRO286, and PRO358 Toll homologues by culturing cells transformed or transfected with a vector containing nucleic acid encoding these proteins (e.g. DNA40021, DNA42663, and DNA47361, respectively). It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PRO285, PRO286, PRO358, or their variants. For instance, the PRO285, PRO286 or PRO358 sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO285, PRO286, or PRO358 may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO285, PRO286, or PRO358.

1.               Isolation of DNA Encoding PRO285, PRO286, or PRO358

20               DNA encoding PRO285, PRO286, or PRO358 may be obtained from a cDNA library prepared from tissue believed to possess the PRO285, PRO286, or PRO358 mRNA and to express it at a detectable level. Accordingly, human PRO285, PRO286, or PRO358 DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The underlying gene may also be obtained from a genomic library or by oligonucleotide synthesis. In addition to the libraries described in the Examples, DNA encoding the human Toll proteins of the present invention can be isolated, for example, from spleen cells, or peripheral blood leukocytes (PBL).

Libraries can be screened with probes (such as antibodies to the PRO285, PRO286, or PRO358 protein or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO285, PRO286, or PRO358 is to use PCR methodology [Sambrook et al., *supra*; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of

labeling are well known in the art, and include the use of radiolabels like  $^{32}\text{P}$ -labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and  
5 aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as ALIGN, DNASTar, and INHERIT which employ various algorithms to measure homology/sequence  
10 identity.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may  
15 not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for the production of the human Toll proteins and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or  
20 amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of transfection are known to the ordinarily skilled artisan, for example,  
25  $\text{CaPO}_4$  and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with  
30 *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into  
35 yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be

used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635).

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for human Toll-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism.

Suitable host cells for the expression of glycosylated human Toll proteins are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO285, PRO286, or PRO358 may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The PRO285, PRO286 and PRO358 proteins may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the PRO285, PRO286 or PRO358 DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from

the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, *e.g.*, the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, *e.g.*, ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, *e.g.*, the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO285, PRO286, or PRO358 nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding the PRO285, PRO286 or PRO358 protein to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the *tac* promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding PRO285, PRO286, or PRO358.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or

other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

PRO285, PRO286 or PRO358 transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the PRO285, PRO286, or PRO358 polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO285, PRO286, or PRO358 coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO285, PRO286, or PRO358.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO285, PRO286, or PRO358 in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

#### 4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO285, PRO286 or PRO358 polypeptides or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO285, PRO286 or PRO358 DNA and encoding a specific antibody epitope.

#### 5. Purification of Polypeptide

Forms of PRO285, PRO286 or PRO358 may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (*e.g.* Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO285, PRO286 or PRO358 can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify PRO285, PRO286, or PRO358 from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the Toll proteins. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular Toll protein produced.

#### E. Uses for the Toll proteins and encoding nucleic acids

Nucleotide sequences (or their complement) encoding the Toll proteins of the present invention have various applications in the art of molecular biology, including uses as

hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. Toll nucleic acid will also be useful for the preparation of PRO285, PRO286 and PRO358 polypeptides by the recombinant techniques described herein.

The full-length native sequence DNA40021, DNA42663, and DNA47361 genes,  
5 encoding PRO285, PRO286, and PRO358, respectively, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length gene or to isolate still other genes (for instance, those encoding naturally-occurring variants of PRO285, PRO286, or PRO358 or their further human homologues, or homologues from other species) which have a desired sequence identity to the PRO285, PRO286, or PRO358 sequence disclosed in Figs. 1,  
10 3 and 12A-B, respectively. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from the nucleotide sequence of Figure 2 (SEQ ID NO: 2), or Figure 4 (SEQ ID NO: 4), or Figure 13A-B (SEQ ID NO: 14), or from genomic sequences including promoters, enhancer elements and introns of native sequence. By way of example, a screening method will comprise isolating the coding region of the PRO285, or  
15 PRO286, or PRO358 gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the PRO285, PRO286, or PRO358 gene (DNAs 40021, 42663 and  
20 47361) of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related Toll sequences.

25 Nucleotide sequences encoding a Toll protein herein can also be used to construct hybridization probes for mapping the gene which encodes that Toll protein and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and  
30 hybridization screening with libraries.

The human Toll proteins of the present invention can also be used in assays to identify other proteins or molecules involved in Toll-mediated signal transduction. For example, PRO285, PRO286, and PRO358 are useful in identifying the as of yet unknown natural ligands of human Tolls, or other factors that participate (directly or indirectly) in the activation of and/or  
35 signaling through a human Toll receptor, such as potential Toll receptor associated kinases. In addition, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Screening assays can be designed to find lead compounds that mimic the biological activity of a native Toll polypeptide or a ligand for a native

Toll polypeptide. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein  
5 binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.

*In vitro* assays employ a mixture of components including a Toll receptor polypeptide, which may be part of fusion product with another peptide or polypeptide, e.g., a tag for detecting or anchoring, etc. The assay mixtures may further comprise (for binding  
10 assays) a natural intra- or extracellular Toll binding target (i.e. a Toll ligand, or another molecule known to activate and/or signal through the Toll receptor). While native binding targets may be used, it is frequently preferred to use portion of such native binding targets (e.g. peptides), so long as the portion provides binding affinity and avidity to the subject Toll protein conveniently measurable in the assay. The assay mixture also contains a candidate  
15 pharmacological agent. Candidate agents encompass numerous chemical classes, through typically they are organic compounds, preferably small organic compounds, and are obtained from a wide variety of sources, including libraries of synthetic or natural compounds. A variety of other reagents may also be included in the mixture, such as, salts, buffers, neutral proteins, e.g. albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial agents, etc.

*In vitro* binding assays, the resultant mixture is incubated under conditions whereby, but for the presence of the candidate molecule, the Toll protein specifically binds the cellular binding target, portion or analog, with a reference binding affinity. The mixture components can be added in any order that provides for the requisite bindings and incubations may be performed at any temperature which facilitates optimal binding. Incubation periods are  
20 likewise selected for optimal binding but also minimized to facilitate rapid high-throughput screening.

After incubation, the agent-biased binding between the Toll protein and one or more binding targets is detected by any convenient technique. For cell-free binding type assays, a separation step is often used to separate bound from unbound components. Separation may  
30 be effected by precipitation (e.g. TCA precipitation, immunoprecipitation, etc.), immobilization (e.g. on a solid substrate), etc., followed by washing by, for example, membrane filtration (e.g. Whatman's P-18 ion exchange paper, Polyfiltronic's hydrophobic GFC membrane, etc.), gel chromatography (e.g. gel filtration, affinity, etc.). For Toll-dependent transcription assays, binding is detected by a change in the expression of a Toll-dependent reporter.

Detection may be effected in any convenient way. For cell-free binding assays, one of the components usually comprises or is coupled to a label. The label may provide for direct detection as radioactivity, luminescence, optical or electron density, etc., or indirect detection, such as, an epitope tag, an enzyme, etc. A variety of methods may be used to detect the label depending on the nature of the label and other assay components, e.g. through optical  
35



or electron density, radiative emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, etc.

Nucleic acids which encode PRO285, PRO286, or PRO358, or their modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding PRO285 or PRO286 can be used to clone genomic DNA encoding PRO285, PRO286, or PRO358 in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding PRO285, PRO286, or PRO358. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding PRO285, PRO286, or PRO358 introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding PRO285, PRO286, or PRO358. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human vertebrate (e.g. mammalian) homologues of PRO285 or PRO286 or PRO358 can be used to construct a "knock out" animal which has a defective or altered gene encoding PRO285 or PRO286 or PRO358, as a result of homologous recombination between the endogenous gene encoding PRO285, PRO286, or PRO358 protein and altered genomic DNA encoding PRO285, PRO286, or PRO358 introduced into an embryonic cell of the animal. For example, cDNA encoding PRO285, PRO286, or PRO358 can be used to clone genomic DNA encoding PRO285, PRO286, or PRO358 in accordance with established techniques. A portion of the genomic DNA encoding PRO285, PRO286, or PRO358 can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells*:

*A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the PRO285, PRO286, or PRO358 polypeptides.

Nucleic acid encoding the Toll polypeptide disclosed herein may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik *et al.*, Proc. Natl. Acad. Sci. USA **83**, 4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau *et al.*, Trends in Biotechnology **11**, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu *et al.*, J. Biol. Chem. **262**, 4429-4432 (1987); and Wagner *et al.*, Proc. Natl. Acad. Sci. USA **87**, 3410-3414 (1990). For review of the currently known gene marking and gene therapy protocols see Anderson *et al.*, Science **256**, 808-813 (1992).

The various uses listed in connection with the Toll proteins herein, are also available for agonists of the native Toll receptors, which mimic at least one biological function of a native Toll receptor.

F. Anti-Toll protein Antibodies

5 The present invention further provides anti-Toll protein antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

1. Polyclonal Antibodies

10 The anti-Toll protein antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the PRO285 and PRO286 polypeptides or a fusion protein thereof. It may be useful to  
15 conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The  
20 immunization protocol may be selected by one skilled in the art without undue experimentation.

2. Monoclonal Antibodies

The anti-Toll protein antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or  
25 other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the PRO285, PRO286, or PRO358 polypeptides or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly  
30 myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include

hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Rockville, Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO285, PRO286, or PRO358. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., supra] or by covalently joining to the immunoglobulin coding sequence all or

part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5           The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino  
10   acid residue or are deleted so as to prevent crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### 3.     Humanized and Human Antibodies

15           The anti-Toll antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human  
20   immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues  
25   which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody  
30   optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from  
35   a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the

corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

#### 4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities may be for the PRO285, PRO286, or PRO358 protein, the other one for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit. It is also possible to prepare bispecific antibodies, having specificities to two different Toll-like proteins, such as, any two of the Toll homologues disclosed in the present application, or a Toll protein disclosed herein, and a Toll protein known in the art, e.g., TLR2. Such bispecific antibodies could block the recognition of different pathogen patterns by Toll receptors, and are, therefore, expected to have significant benefits in the treatment of sepsis and septic shock.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity

chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

#### 5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### G. Uses for anti-Toll protein antibodies

The anti-Toll antibodies of the invention have various utilities. For example, anti-PRO285, anti-PRO286, anti-PRO-358, and anti-TLR2 antibodies may be used in diagnostic assays for PRO285, PRO286, PRO358, or TLR2 *e.g.*, detecting its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as <sup>3</sup>H, <sup>14</sup>C, <sup>32</sup>P, <sup>35</sup>S, or <sup>125</sup>I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

Anti-PRO285, anti-PRO286, anti-PRO358, or anti-TLR2 antibodies also are useful for the affinity purification of these proteins from recombinant cell culture or natural sources. In this process, the antibodies against these Toll proteins are immobilized on a suitable support, such as a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO285, PRO286, PRO358, or TLR2 protein which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the protein from the antibody.

Anti-Toll receptor (i.e., anti-PRO285, anti-PRO286, anti-PRO358, or anti-TLR2 antibodies) may also be useful in blocking the biological activities of the respective Toll receptors. The primary function of the family of Toll receptors is believed to be to act as pathogen pattern recognition receptors sensing the presence of conserved molecular pattern present on microbes. Lipopolysaccharides (LPS, also known as endotoxins), potentially lethal molecules produced by various bacteria, bind to the lipopolysaccharide binding protein (LBP) in the blood. The complex formed then activates a receptor known as CD14. There is no consensus in the art about what happens next. According to a hypothesis, CD14 does not directly instruct macrophages to produce cytokines, cell adhesion proteins and enzymes involved in the production of lower molecular weight proinflammatory mediators, rather enables LPS to activate a second receptor. Alternatively, it has been suggested that LPS may activate certain receptors directly, without help from LBP or CD14. The data disclosed in the present application indicate that the human toll-like receptors are signaling receptors that are activated by LPS in an LBP and CD14 responsive manner. As this mechanism, under pathophysiologic conditions can lead to an often fatal syndrome called septic shock, anti-Toll receptor antibodies (just as other Toll receptor antagonists) might be useful in the treatment of septic shock. It is foreseen that the different Toll receptors might recognize different pathogens, e.g., various strains of Gram-negative or Gram-positive bacteria. Accordingly, in certain situations, combination therapy with a mixture of antibodies specifically binding different Toll receptors, or the use of bispecific anti-Toll antibodies may be desirable.

It is specifically demonstrated herein that anti-huTLR2 antibodies are believed to be specifically useful in blocking the induction of this receptor by LPS. As it has been shown that LPS exposure can lead to septic shock (Parrillo, *N. Engl. J. Med.* **328**, 1471-1477 [1993]), anti-huTLR2 antibodies are potentially useful in the treatment of septic shock.

The foregoing therapeutic and diagnostic uses listed in connection with the anti-Toll receptor antibodies are also applicable to other Toll antagonists, i.e., other molecules (proteins, peptides, small organic molecules, etc.) that block Toll receptor activation and/or signal transduction mediated by Toll receptors.

In view of their therapeutic potentials, the Toll proteins (including variants of the native Toll homologues), and their agonists and antagonists (including but not limited to



anti-Toll antibodies) are incorporated in compositions suitable for therapeutic use. Therapeutic compositions are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th Edition, Osol, A. Ed. 1980) in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronic or PEG.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, *supra*.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.

Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems.

Suitable examples of sustained release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices include polyesters, hydrogels, polylactides (U.S. Patent 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (U. Sidman *et al.*, Biopolymers 22 (1): 547-556 [1983]), poly (2-hydroxyethyl-methacrylate) (R. Langer, *et al.*, J. Biomed. Mater. Res. 15: 167-277 [1981] and R. Langer, Chem. Tech. 12: 98-105 [1982]), ethylene vinyl acetate (R. Langer *et al.*, *Id.*) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained release compositions also include liposomes. Liposomes containing a molecule within the scope of the present invention are prepared by methods known *per se*: DE 3,218,121; Epstein *et al.*, Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52322; EP 36676A; EP 88046; EP 143949; EP 142641; Japanese patent

application 83-118008; U.S. patents 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal NT-4 therapy.

5 An effective amount of the active ingredient will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 1 µg/kg to up to 100 mg/kg or more, depending on the factors mentioned above.

10 Typically, the clinician will administer a molecule of the present invention until a dosage is reached that provides the required biological effect. The progress of this therapy is easily monitored by conventional assays.

\*\*\*\*\*

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

#### EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Rockville, Maryland.

#### EXAMPLE 1

##### Isolation of cDNA clones Encoding Human PRO285

25 A proprietary expressed sequence tag (EST) DNA database (LIFESEQ<sup>TM</sup>, Incyte Pharmaceuticals, Palo Alto, CA) was searched and an EST (#2243209) was identified which showed homology to the *Drosophila* Toll protein.

Based on the EST, a pair of PCR primers (forward and reverse):

TAAAGACCCAGCTGTGACCG (SEQ ID NO:5)

30 ATCCATGAGCCTCTGATGGG (SEQ ID NO: 6), and

a probe:

ATTTATGTCTCGAGGAAAGGGACTGGTTACCAGGGCAGCCAGTTC (SEQ ID NO: 7)

were synthesized.

mRNA for construction of the cDNA libraries was isolated from human placenta tissue. The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA (Fast Track 2). The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into the cloning vector pCR2.1 (Invitrogen, Inc.) using reagents

and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System). The double stranded cDNA was sized to greater than 1000 bp and the cDNA was cloned into BamHI/NotI cleaved vector. pCR2.1 is a commercially available plasmid, designed for easy cloning of PCR fragments, that carries AmpR and KanR genes for selection, and LacZ gene for blue-white selection.

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO285 gene using the probe oligonucleotide and one of the PCR primers.

A cDNA clone was sequenced in entirety. The entire nucleotide sequence of DNA40021 (encoding PRO285) is shown in Figure 2 (SEQ ID NO:2). Clone DNA40021 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 61-63 (Fig. 2). The predicted polypeptide precursor is 1049 amino acids long, including a putative signal peptide at amino acid positions 1-29, a putative transmembrane domain between amino acid positions 837-860, and a leucine zipper pattern at amino acid positions 132-153 and 704-725, respectively. It is noted that the indicated boundaries are approximate, and the actual limits of the indicated regions might differ by a few amino acids. Clone DNA40021 has been deposited with ATCC (designation: DNA40021-1154) and is assigned ATCC deposit no.209389.

Based on a BLAST and FastA sequence alignment analysis (using the ALIGN computer program) of the full-length sequence is a human analogue of the *Drosophila* Toll protein, and is homologous to the following human Toll proteins: Toll1 (DNAX# HSU88540-1, which is identical with the random sequenced full-length cDNA #HUMRSC786-1); Toll2 (DNAX# HSU88878-1); Toll3 (DNAX# HSU88879-1); and Toll4 (DNAX# HSU88880-1).

## EXAMPLE 2

### Isolation of cDNA clones Encoding Human PRO286

A proprietary expressed sequence tag (EST) DNA database (LIFESEQ<sup>TM</sup>, Incyte Pharmaceuticals, Palo Alto, CA) was searched and an EST (#694401) was identified which showed homology to the *Drosophila* Toll protein.

Based on the EST, a pair of PCR primers (forward and reverse):

GCCGAGACAAAAACGTTCTCC (SEQ ID NO:8)

CATCCATGTTCTCATCCATTAGCC (SEQ ID NO: 9), and

a probe:

TCGACAACCTCATGCAGAGCATCAACCAAAGCAAGAAAACAGTATT (SEQ ID NO: 10)

were synthesized.

mRNA for construction of the cDNA libraries was isolated from human placenta tissue. This RNA was used to generate an oligo dT primed cDNA library in the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System). pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the XhoI/NotI cDNA cloning sites. The cDNA was primed

with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized to greater than 1000 bp appropriately by gel electrophoresis, and cloned in a defined orientation into XhoI/NotI-cleaved pRK5D.

5 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO286 gene using the probe oligonucleotide identified above and one of the PCR primers.

10 A cDNA clone was sequenced in entirety. The entire nucleotide sequence of DNA42663 (encoding PRO286) is shown in Figure 4 (SEQ ID NO:4). Clone DNA42663 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 57-59 (Fig. 4). The predicted polypeptide precursor is 1041 amino acids long, including a putative signal peptide at amino acid positions 1-26, a potential transmembrane domain at amino acid positions 826-848, and leucine zipper patterns at amino acids 130-151, 206-227, 662-684, 669-690 and 693-614, respectively. It is noted that the indicated boundaries are  
15 approximate, and the actual limits of the indicated regions might differ by a few amino acids.

Clone DNA42663 has been deposited with ATCC (designation: DNA42663-1154) and is assigned ATCC deposit no. 209386.

Based on a BLAST and FastA sequence alignment analysis (using the ALIGN computer program) of the full-length sequence of PRO286, it is a human analogue of the  
20 *Drosophila* Toll protein, and is homologous to the following human Toll proteins: Toll1 (DNAX# HSU88540-1, which is identical with the random sequenced full-length cDNA #HUMRSC786-1); Toll2 (DNAX# HSU88878-1); Toll3 (DNAX# HSU88879-1); and Toll4 (DNAX# HSU88880-1).

### EXAMPLE 3

#### Isolation of cDNA clones Encoding Human PRO358

25 The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from known members of the human Toll receptor family were used to search EST databases. The EST databases included public EST databases (e.g., GenBank) and a proprietary EST database (LIFESEQ<sup>TM</sup>, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 [Altschul et al., Methods in  
30 Enzymology, 266:460-480 (1996)] as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons resulting in a BLAST score of 70 (or in some cases, 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington).

35 An EST was identified in the Incyte database (INC3115949).

Based on the EST sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO358.

A pair of PCR primers (forward and revers ) were synthesized:

TCCCACCAGGTATCATAAACTGAA

(SEQ ID NO:15)

TTATAGACAATCTGTTCTCATCAGAGA

(SEQ ID NO:16)

- 5 A probe was also synthesized:

AAAAAGCATACTTGGAATGGCCCAAGGATAGGTGTAAATG

(SEQ ID NO:17)

- 10 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO358 gene using the probe oligonucleotide and one of the PCR primers.

- 15 RNA for construction of the cDNA libraries was isolated from human bone marrow (LIB256). The cDNA libraries used to isolated the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

- 20 DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO358 (Figures 13A and 13B, SEQ ID NO:14) and the derived protein sequence for PRO358 (Figures 12A and 12B, SEQ ID NO:13).

- 25 The entire nucleotide sequence of the clone identified (DNA47361) is shown in Figure 13A-B (SEQ ID NO:14). Clone DNA47361 contains a single open reading frame with an apparent translational initiation site (ATG start signal) at nucleotide positions underlined in Figures 13A and 13B. The predicted polypeptide precursor is 811 amino acids long, including a putative signal sequence (amino acids 1 to 19), an extracellular domain (amino acids 20 to 575, including leucine rich repeats in the region from position 55 to position 575), a putative transmembrane domain (amino acids 576 to 595). Clone DNA47361 (designated DNA47361-30 1249) has been deposited with ATCC and is assigned ATCC deposit no. 209431.

- 35 Based on a BLAST and FastA sequence alignment analysis (using the ALIGN computer program) of the full-length sequence of PRO286, it is a human analogue of the *Drosophila* Toll protein, and is homologous to the following human Toll proteins: Toll1 (DNAX# HSU88540-1, which is identical with the random sequenced full-length cDNA #HUMRSC786-1); Toll2 (DNAX# HSU88878-1); Toll3 (DNAX# HSU88879-1); and Toll4 (DNAX# HSU88880-1).

## EXAMPLE 4

Use of PRO285, PRO286 and PRO358 DNA as a hybridization probe

The following method describes use of a nucleotide sequence encoding PRO285, PRO286 or PRO358 as a hybridization probe. In the following description, these proteins are collectively referred to as "Toll homologues."

DNA comprising the coding sequence of a Toll homologue is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of these particular Toll proteins in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled Toll homologue-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding full-length native sequence Toll homologue can then be identified using standard techniques known in the art.

## EXAMPLE 5

Expression of PRO285, PRO286, and PRO358 in *E. coli*

This example illustrates preparation of an unglycosylated form of PRO285, PRO285 or PRO358 ("Toll homologues") by recombinant expression in *E. coli*.

The DNA sequence encoding a Toll homologue is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO285 coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized Toll homologue can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

#### EXAMPLE 6

##### Expression of PRO285, PRO286 and PRO358 in mammalian cells

This example illustrates preparation of a glycosylated form of PRO285, PRO286 and PRO358 ("Toll homologues") by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the Toll homologue-encoding DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the Toll homologue-encoding DNA using ligation methods such as described in Sambrook et al., supra. The resulting vector is called pRK5-PRO285, -PRO286 or -PRO358, as the case may be.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5-PRO285, -PRO286, or -PRO358 DNA is mixed with about 1 µg DNA encoding the VA RNA gene [Thimmappaya et al., Cell, 31:543 (1982)] and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl<sub>2</sub>. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 µCi/ml <sup>35</sup>S-cysteine and 200 µCi/ml <sup>35</sup>S-methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO285 polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, Toll homologue DNA may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 µg pRK5-PRO(285)/(286)/(358) DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 µg/ml bovine insulin and 0.1 µg/ml bovine transferrin. After about four days, the

conditioned media is centrifuged and filtered to remove cells and debris. The sample containing the corresponding expressed Toll homologue can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, the Toll homologues can be expressed in CHO cells.

- 5 The pRK5-vectors can be transfected into CHO cells using known reagents such as  $\text{CaPO}_4$  or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as  $^{35}\text{S}$ -methionine. After determining the presence of PRO285, PRO286 or PRO358 polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are  
10 incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed Toll homologue can then be concentrated and purified by any selected method.

- Epitope-tagged Toll homologues may also be expressed in host CHO cells. The Toll homologue DNA may be subcloned out of the pRK5 vector. The subclone insert can undergo  
15 PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the  
20 expressed poly-His tagged Toll homologue can then be concentrated and purified by any selected method, such as by  $\text{Ni}^{2+}$ -chelate affinity chromatography.

#### EXAMPLE 7

##### Expression of PRO285, PRO286, and PRO358 in Yeast

- The following method describes recombinant expression of PRO285, PRO286 or  
25 PRO358 ("Toll homologues") in yeast.

- First, yeast expression vectors are constructed for intracellular production or secretion of a Toll homologue from the ADH2/GAPDH promoter. DNA encoding the desired Toll homologue, a selected signal peptide and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression. For secretion, DNA  
30 encoding the selected Toll homologue can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, the yeast alpha-factor secretory signal/leader sequence, and linker sequences (if needed) for expression.

- Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The  
35 transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant Toll homologues can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then



concentrating the medium using selected cartridge filters. The concentrate containing the Toll homologue may further be purified using selected column chromatography resins.

#### EXAMPLE 8

##### Expression of PRO285, PRO286 and PRO358 in Baculovirus Infected Insect Cells

5           The following method describes recombinant expression of PRO285, PRO286 and PRO358 ("Toll homologues") in Baculovirus infected insect cells.

          The Toll homologue coding sequence is fused upstream of an epitope tag contained with a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including  
10       plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the Toll homologue coding sequence or the desired portion of the coding sequence (such as the sequence encoding the extracellular domain) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into  
15       the expression vector.

          Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold<sup>TM</sup> virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection  
20       and protein expression is performed as described by O'Reilley et al., Baculovirus expression vectors: A laboratory Manual, Oxford: Oxford University Press (1994).

          Expressed poly-his tagged Toll homologue can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., *Nature*, **362**:175-179 (1993). Briefly, Sf9  
25       cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% Glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% Glycerol, pH 7.8) and filtered through a 0.45 µm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed  
30       volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% Glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A<sub>280</sub> baseline  
35       again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or western blot with Ni<sup>2+</sup>-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged PRO285 are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) Toll homologues can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

#### EXAMPLE 9

##### NF- $\kappa$ B assay

As the Toll proteins signal through the NF- $\kappa$ B pathway, their biological activity can be tested in an NF- $\kappa$ B assay. In this assay Jurkat cells are transiently transfected using Lipofectamine reagent (Gibco BRL) according to the manufacturer's instructions. 1 $\mu$ g pB2XLuc plasmid, containing NF- $\kappa$ B-driven luciferase gene, is cotransfected with 1 $\mu$ g pSR $\alpha$ N expression vector with or without the insert encoding PRO285 or PRO286. For a positive control, cells are treated with PMA (phorbol myristyl acetate; 20 ng/ml) and PHA (phytohaemagglutinin, 2 $\mu$ g/ml) for three to four hours. Cells are lysed 2 or 3 days later for measurement of luciferase activity using reagents from Promega.

#### EXAMPLE 10

##### Preparation of Antibodies that Bind PRO285, PRO286, or PRO358

This example illustrates preparation of monoclonal antibodies which can specifically bind PRO285, PRO286 or PRO358 ("Toll homologues").

Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified Toll homologues, fusion proteins containing the desired Toll homologue, and cells expressing recombinant Toll homologues on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the Toll homologue immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect PRO285 antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of a Toll homologue. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against the corresponding Toll homologue. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against a Toll homologue is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-Toll homologue monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

#### EXAMPLE 11

##### HuTLR2 mediates lipopolysaccharide (LPS) induced cellular signaling

###### Methods

**Reagents** [<sup>3</sup>H]-labeled, unlabeled, LCD25 and *S. minnesota* R595 LPS were from List Biochemicals (Campbell, CA) and all other LPS were from Sigma Chemical Co. (St. Louis, MO). LP was supplied as conditioned media from 293 cells transfected with a human LBP expression vector. The TLR2-Fc fusion protein was produced by baculovirus system, and purified as described. Mark *et al.*, J. Biol. Chem. **269**, 10720-10728 (1994).

**Construction of Expression Plasmids** A cDNA encoding human TLR2 was cloned from human fetal lung library. The predicted amino acid sequence matched that of the previously published sequence (Rock *et al.*, *supra*), with the exception of a glu to asp substitution at amino acid 726. The amino acid terminal epitope tag version of TLR2 (dG.TLR2) was constructed by adding an XhoI restriction site immediately upstream of leucine at position 17 (the first amino acid of the predicted mature form of TLR2) and linking this to amino acids 1-53 of herpes simplex virus type 1 glycoprotein D as described. Mark *et al.*, *supra*. PCR products were sequenced and subcloned into a mammalian expression vector that contains the puromycin resistance gene. C-terminal truncation variants of gD.TLR2 were constructed by digestion of the cDNA at either a BlnI (variant Δ1) or NsiI (variant Δ2) site present in the coding sequence of the intracellular domain and at a NotI site present in the 3' polylinker of the expression vector followed by ligation of oligonucleotide linkers.

Δ1: 5'-TCA GCG GTA AGC-3' (SEQ ID NO: 18) and

5'-GGC CGC TTA CCG C-3' (SEQ ID NO: 19)

Δ2: 5'-TAA GCT TAA CG-3' (SEQ ID NO: 20) and

5'-GGC CGC TTA AGC TTA TGC A-3' (SEQ ID NO: 21).

The CD4/TLR2 chimera was constructed by PCR and contained amino acids 1-205 (the signal peptide and two immunoglobulin-like domains) of human CD4 fused to amino acids 588-784 (the transmembrane and intracellular domain) of human TLR2 with a linker-encoded valine at the junction of the CD4 and TLR2 sequences. The pGL3.ELAM.tk reporter plasmid contained the sequence

5'-GGT ACC TTC TGA CAT CAT TGT AAT TTT AAG CAT CGT GGA TAT TCC CGG GAA AGT  
TTT TGG ATG CCA TTG GGG ATT TCC TCT TTA GAT CTG GCG CGG TCC CAG GTC CAC  
TTC GCA TAT TAA GGT GAC GCG TGT GGC CTC GAA CAC CGA GCG ACC CTG CAG CGA  
CCC GCA AGC TT-3' (SEQ ID NO: 22),

- 5 inserted between the SacI and HindIII sites of the luciferase reported plasmid pGL3 (Promega). The C-terminal epitope tag version of LBP (LBP-FLAG) was constructed by PCR through the addition of an AscI site in place of the native stop codon and the subcloning of this fragment into pRK5-FLAG resulting in the C-terminal addition of amino acids GRA DYK DDD DK (SEQ ID NO: 23).

- 10 *Stable cell lines/pools* 293 human embryonic kidney cells were grown in LGDMEM/HAM's F12 (50:50) media supplemented with 10% FBS, 2 mM glutamine, and penicillin/streptomycin. For stable expression of gD.TLR2, cells were transfected with the gD.TLR2 expression vector and selected for puromycin resistance at a final concentration of 1 µg/ml. A stable pool of cells (293-TLR2 pop1) was isolated by FACS using an antibody to the gD  
15 tag. Both the pool and the single cell clone (293-TLR2 clone 1) were characterized by FACS and western blot analyses as described in Mark *et al.*, *supra*.

*Luciferase reporter assay and electrophoretic mobility shift assay (EMSA)*

- 29332 parental or stable cells (2 x 10<sup>5</sup> cells per well) were seeded into six-well plates, and transfected on the following day with the expression plasmids together with 0.5 µg of the  
20 luciferase reporter plasmid pGL3-ELAM.tk and 0.05 µg of the *Renilla* luciferase reported vector as an internal control. After 24 hours, cells were treated with either LPS, LBP or both LPS and LBP and reporter gene activity was measured. Data are expressed as relative luciferase activity by dividing firefly luciferase activity with that of *Renilla* luciferase. For EMSA, nuclear extracts  
25 were prepared and used in a DNA-binding reaction with a 5'-[<sup>32</sup>P]-radiolabelled oligonucleotides containing a consensus NF-κB binding site (Santa Cruz Biotechnology, sc-2511). The identity of NF-κB in the complex was confirmed by supershift with antibodies to NF-κB (data not shown).

*RNA expression*

- The tissue northern blot was purchased from Clontech and hybridized with a probe encompassing the extracellular domain of TLR2. Polyadenylated  
30 mRNA was isolated from 293 cells or 293-TLR2 cells and Northern blots were probed with human IL-8 cDNA fragment. TLR2 expression was determined using quantitative PCR using real time "taqman<sup>TM</sup>" technology and analyzed on a Model 770 Sequence Detector (Applied Biosystems, Foster City, CA, USA) essentially as described (Luoh *et al.*, *J. Mol. Endocrinol.* 18, 77-85 [1997]). Forward and reverse primers,

- 35 5'-GCG GGA AGG ATT TTG GGT AA-3' SEQ ID NO: 24, and  
5'-GAT CCC AAC TAG ACA AAG ACT GGT C-3' SEQ ID NO: 25

were used with a hybridization probe,

5'-TGA GAG CTG CGA TAA AGT CCT AGG TTC CCA TAT-3' SEQ ID NO: 26

labeled on the 5' nucleotide with a reporter dye FAM and the 3' nucleotide with a quenching dye TAMRA. Macrophage/monocytes were treated 16 h with 1 µg/ml of LPS.

*Receptor binding assay* To determine the direct binding, 20 ng of [<sup>3</sup>H]-LPS was mixed with 600 ng of TLR2-Fc in 100 µl of binding buffer (150 mM NaCl, 20 mM Hepes, 0.03% BSA) containing 15 µl protein A sepharose. After 3h-incubation at room temperature, protein A sepharose samples were washed twice with cold PBS/0.1% NP-40 and resuspended in binding buffer including 1% SDS and 25 mM EDTA, and counted.

### Results

In *Drosophila*, the Toll receptor is required for embryonic dorso-ventral pattern formation and also participated in an anti-fungal immune response in the adult fly. Belvin and Anderson, Ann. Rev. Cell. Biol. **12**, 393-416 (1996); Lemaitre *et al.*, Cell **86**, 973-983 (1996). Toll is a type I transmembrane protein containing an extracellular domain with multiple leucine-rich repeats (LRRs) and a cytoplasmic domain with sequence homology to the interleukin-1 receptor (IL-1R), and several plant disease-resistance proteins. Activation of Toll leads to induction of genes through the activation of the NF-κB pathway. As noted before, there are several human homologues that have been cloned, some of which are disclosed as novel proteins in the present application. These human proteins mirror the topographic structure of their *Drosophila* counterpart. Overexpression of a constitutively active mutant of one human TLR (TLR4) has been shown to lead to the activation of NF-κB and induction of the inflammatory cytokines and constimulatory molecules (Medzhitov *et al.*, and Rock *et al.*, *supra.*).

To examine if human TLRs might be involved in LPS-induced cell activation, we first investigated the expression of TLRs in a variety of immune tissues. One of the TLRs, TLR2, was found to be expressed in all lymphoid tissues examined with the highest expression in peripheral blood leukocytes (Figure 5a). Expression of TLR2 is enriched in monocytes/macrophages, the primary CD14-expressing and LPS-responsive cells. Interestingly, tLR2 is up-regulated upon stimulation of isolated monocytes/macrophages with LPS (Figure 5b), similar to what has been reported for CD14 (Matsuura *et al.*, Eur. J. Immunol. **22**, 1663-1665 [1992]; Croston *et al.*, J. Biol. Chem. **270**, 16514-16517 [1995]).

This result prompted us to determine, if TLR2 is involved in LPS-mediated cellular signaling. We engineered human embryonic kidney 293 cells to express a version of TLR2 (gD-TLR2) containing an amino-terminal epitope-tag. A stable pool of clones as well as an individual clone was isolated and shown to express a novel protein of about 105 kDa (Figure 6b), consistent with the predicted size of TLR2 (~89 kDa) and the presence of 4 potential sites for N-linked glycosylation. We examined the response of 293 or 293-TLR2 cells and LBP by measuring the expression of a reported gene driven by the NF-κB responsive enhancer of the E-selectin gene (Croston *et al.*, *supra.*). While neither LPS nor LBP treatment alone resulted in significant gene activation, addition of both LPS and LBP resulted in substantial induction of reporter gene activity in cells expressing TLR2, but not in control 293 cells (Figure 6a). Furthermore, using an electrophoretic mobility shift assay (EMSA), we found that LPS, in

combination with LBP, induced NF- $\kappa$ B activity in TLR2 expressing cells (Figure 6c). The kinetics of LPS-induced NF- $\kappa$ B activity in 293-TLR2 cells resembled that of myeloid and nonmyeloid cells (Delude *et al.*, *J. Biol. Chem.* **269**, 22253-22260 [1994]; Lee *et al.*, *Proc. Natl. Acad. Sci. USA* **90**, 9930-9934 [1993]) in that nuclear localization of NF- $\kappa$ B is maximal within 5 30 minutes following exposure to LPS. Activation of NF- $\kappa$ B by LPS/LBP in 293-TLR2 cells does not require *de novo* protein synthesis, since pretreatment with cycloheximide (Figure 6c) or actinomycin D (not shown) does not inhibit NF- $\kappa$ B activation.

Both the membrane-bound form of CD14 (mCD14), which is present on myeloid cells, and soluble CD14 (sCD14) which is present in plasma (Bazil *et al.*, *Eur. J. Immunol.* **16**, 10 1583-1589 [1986]), have been shown to enhance the responsiveness of cells to LPS. We observed that 293 cells express little or no CD14 on their surface (data not shown). However, transient transfection of 293 cells which mCD14 increased the sensitivity and magnitude of TLR2-mediated LPS responsiveness (Figure 6d).

The data presented above suggested that TLR2 might function as a signaling 15 transducer for LPS. To examine the role of the intracellular domain of TLR2 in mediating the LPS response, we determined if TLR2 variants with C-terminal truncations of either 13 (TLR2- $\Delta$ 1) or 141 amino acids (TLR2- $\Delta$ 2) could regulate the ELAM reporter in transiently transfected 293 cells. We observed that both C-terminal truncation variants were defective for activation of the reporter gene although we could detect expression of these receptors at the cells surface 20 by FACS analysis (not shown) and by Western blot (Figure 7c). The region of the intracellular domain deleted in TLR2- $\Delta$ 1 bears striking similarity to a region of the IL-1R intracellular domain that is required for association with the IL-1R-associated kinase IRAK (Croston *et al.*, *supra*) (Figure 7b). We also demonstrated that the extracellular domain (ECD) of TLR2 is required for LPS-responsiveness in that a TLR2 variant in which the ECD of TLR2 was replaced 25 with a portion of the ECD of CD4 also failed to respond to LPS (Figure 7a and 7b).

LPS is a complex glycolipid consisting of the proximal hydrophobic lipid A moiety, the distal hydrophilic O-antigen polysaccharide region and the core oligosaccharide that joins lipid A and O-antigen structures. In contrast to the lipid A portion, there is a considerable diversity in the O-antigen structures from different Gram-negative bacteria. Lipid A is required 30 for LPS responses, and treatments that remove the fatty acid side chains of lipid A inactivate LPS. We compared the potency of LPS prepared from various Gram-negative bacteria, as well as LPS which had been "detoxified" by alkaline hydrolysis. We observed that LPS isolated from *Escherichia coli* serotype LCD25 was nearly two orders of magnitude more potent than the serologically distinct *Escherichia coli* 055:B5 LPS for activating TLR2 (Figure 8a). LPS 35 prepared from *S. minnesota* R595 LPS is also a potent inducer of TLR2 activity, while TLR2 failed to respond to "detoxified LPS".

We examined if TLR2 binds LPS by determining if a soluble form of the TLR2 extracellular domain (TLR2-Fc) bound  $^3$ H-labeled LPS in an *in vitro* assay. We observed that  $^3$ H-LCD25 LPS bound the TLR2-Fc fusion protein, but did not bind either Fc alone, or fusion

proteins containing the ECD of several other receptors (Figure 8b). This binding was specifically competed with cold LCD25 LPS but not with detoxified LPS. Preliminary analysis of the binding of LPS to TLR2-Fc suggests that the K<sub>d</sub> is relatively low (500-700 nM) and that the kinetics of binding are very slow (data not shown). We speculate that other proteins, such as LBP, might act to enhance the binding of LPS to TLR2 *in vivo*, much like LBP acts to transfer LPS from its free, aggregated (micellar form) to CD14. This is consistent with our *in vivo* results showing that LBP is required to obtain a sensitive response of TLR2 to LPS (Figure 6a).

ILS treatment of macrophages leads to expression of a number of inflammatory cytokines. Similarly expression of TLR2 in 293 cells resulted in a >100 fold-induction of IL-8 mRNA in response to LPS/LBP, while detoxified LPS is inactive in this assay (Figure 9).

These data suggest that TLR2 plays a sentinel role in the innate immune response, the first line of defense against microbial pathogens. TLR2 and CD14 are both expressed on myeloid cells, and their induction is coordinately induced upon LPS treatment. Expression of TLR2 in non-myeloid cells confers LPS responsiveness to normally non-responsive cells by a mechanism that is dependent on LBP and is enhanced by the expression of mCD14. LPS treatment of TLR2 expressing cells results in activation of NF- $\kappa$ B and subsequent induction of genes that initiate the adaptive response such as IL-8 (Figure 9). Our data suggest that TLR2 participates in both sensing the presence of LPS and transmitting this information across the plasma membrane because intact extracellular and intracellular domains are required for LPS responses. Moreover, a region in the C-terminal tail of TLR2 that has homology to a portion of the IL-1R that is required for association with IRAK, is necessary for NF- $\kappa$ B activation.

*Drosophila* Toll and the Toll related-receptor 18 Wheeler play an important role in the induction of antimicrobial peptides in response to bacteria and fungi, respectively. Medzhitov *et al.*, *supra*. Genetic data has implicated Spätzle as a ligand for Toll in dorsoventral patterning and has led to speculation that a homologue of Spätzle might be important for regulation of human TLRs in the immune response. Our observations that activation of TLR2 by LPS is not blocked by cycloheximide and that the extracellular domain of TLR2 is a low affinity receptor for LPS *in vitro* is consistent with a model in which TLR2 participated in LPS recognition. Our data does not exclude the possibility that other proteins (such as a Spätzle homologue) may modify the response of TLR2 to LPS. We note that while extracellular domains of TLR2 and *Drosophila* Toll both contain LRRs, they share less than 20% amino acid identity. Secondly, LRR proteins are Pattern Recognition Receptors (PRRs) for a variety of types of molecules, such as proteins, peptides, and carbohydrates. Dangl *et al.*, *Cell* **91**, 17-24 (1997). Thirdly, the requirement for Spätzle in the *Drosophila* immune response is less clear than that of Toll. Unlike defects in Toll, Spätzle mutants induce normal levels of the antimicrobial peptides Defensin and Attacin and are only partially defective in Cecropin A expression following fungal challenge, and are not defective in activation of Dorsal in response to injury. Lemaitre *et al.*, *Cell* **86**, 973-983 (1996); Lemaitre *et al.*, *EMBO J.* **14**, 536-545 (1995).

As noted before, TLR2 is a member of a large family of human Toll-related receptors, including the three novel receptors (encoded by DNA40021, DNA42663, and DNA47361, respectively) specifically disclosed in the present application. The data presented in this example as well as evidence for the involvement of TLR4 in activation of NF- $\kappa$ B responsive genes, suggest that a primary function of this family of receptors is to act as pathogen pattern recognition receptors sensing the presence of conserved molecular structures present on microbes, originally suggested by Janeway and colleagues (Medzhitov *et al.*, *supra*). The human TLR family may be targets for therapeutic strategies for the treatment of septic shock.

## EXAMPLE 12

### In situ Hybridization

*In situ* hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, to identify sites of gene expression, analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis and aid in chromosome mapping.

*In situ* hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision 1: 169-176 (1994), using PCR-generated  $^{33}\text{P}$ -labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinized in proteinase K (20 g/ml) for 15 minutes at 37°C, and further processed for *in situ* hybridization as described by Lu and Gillett, *supra*. A [ $^{33}\text{P}$ ] UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55°C overnight. The slides were dipped in Kodak NTB2 nuclear track emulsion and exposed for 4 weeks.

### $^{33}\text{P}$ -Riboprobe synthesis

6.0  $\mu\text{l}$  (125 mCi) of  $^{33}\text{P}$ -UTP (Amersham BF 1002, SA<2000 Ci/mmol) were speed vac dried. To each tube containing dried  $^{33}\text{P}$ -UTP, the following ingredients were added:

2.0  $\mu\text{l}$  5x transcription buffer

1.0  $\mu\text{l}$  DTT (100 mM)

2.0  $\mu\text{l}$  NTP mix (2.5 mM : 10  $\mu\text{l}$ ; each of 10 mM GTP, CTP & ATP + 10  $\mu\text{l}$  H<sub>2</sub>O)

1.0  $\mu\text{l}$  UTP (50  $\mu\text{M}$ )

1.0  $\mu\text{l}$  Rnasin

1.0  $\mu\text{l}$  DNA template (1 $\mu\text{g}$ )

1.0  $\mu\text{l}$  H<sub>2</sub>O

1.0  $\mu\text{l}$  RNA polymerase (for PCR products T3 = AS, T7 = S, usually)

The tubes were incubated at 37°C for one hour. 1.0  $\mu\text{l}$  RQ1 DNase were added, followed by incubation at 37°C for 15 minutes. 90  $\mu\text{l}$  TE (10 mM Tris pH 7.6/1mM EDTA pH 8.0) were added, and the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a Microcon-50 ultrafiltration unit, and spun using program 10 (6 minutes). The



filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the final recovery spin, 100 µl TE were added. 1 µl of the final product was pipetted on DE81 paper and counted in 6 ml of Biofluor II.

The probe was run on a TBE/urea gel. 1-3 µl of the probe or 5 µl of RNA Mrk III were added to 3 µl of loading buffer. After heating on a 95°C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, the sample loaded, and run at 180-250 volts for 45 minutes. The gel was wrapped in saran wrap and exposed to XAR film with an intensifying screen in -70°C freezer one hour to overnight.

### <sup>33</sup>P-Hybridization

*Pretreatment of frozen sections* The slides were removed from the freezer, placed on aluminium trays and thawed at room temperature for 5 minutes. The trays were placed in 55°C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml SQ H<sub>2</sub>O). After deproteinization in 0.5 µg/ml proteinase K for 10 minutes at 37°C (12.5 µl of 10 mg/ml stock in 250 ml prewarmed RNase-free RNase buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, 100% ethanol, 2 minutes each.

*Pretreatment of paraffin-embedded sections* The slides were deparaffinized, placed in SQ H<sub>2</sub>O, and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinized in 20 µg/ml proteinase K (500 µl of 10 mg/ml in 250 ml RNase-free RNase buffer; 37°C, 15 minutes) - human embryo, or 8 x proteinase K (100 µl in 250 ml RNase buffer, 37°C, 30 minutes) - formalin tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above.

*Prehybridization* The slides were laid out in plastic box lined with Box buffer (4 x SSC, 50% formamide) - saturated filter paper. The tissue was covered with 50 µl of hybridization buffer (3.75g Dextran Sulfate + 6 ml SQ H<sub>2</sub>O), vortexed and heated in the microwave for 2 minutes with the cap loosened. After cooling on ice, 18.75 ml formamide, 3.75 ml 20 x SSC and 9 ml SQ H<sub>2</sub>O were added, the tissue was vortexed well, and incubated at 42°C for 1-4 hours.

*Hybridization* 1.0 x 10<sup>6</sup> cpm probe and 1.0 µl tRNA (50 mg/ml stock) per slide were heated at 95°C for 3 minutes. The slides were cooled on ice, and 48 µl hybridization buffer were added per slide. After vortexing, 50 µl <sup>33</sup>P mix were added to 50 µl prehybridization on slide. The slides were incubated overnight at 55°C.

*Washes* Washing was done 2x10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25M EDTA, V<sub>F</sub>=4L), followed by RNaseA treatment at 37°C for 30 minutes (500 µl of 10 mg/ml in 250 ml RNase buffer = 20 µg/ml). The slides were washed 2x10 minutes with 2 x SSC, EDTA at room temperature. The stringency wash

conditions were as follows: 2 hours at 55°C, 0.1 x SSC, EDTA (20 ml 20 x SSC + 16 ml EDTA,  $V_f=4L$ ).

### Results

#### PRO285 (DNA40021)

5 The expression pattern of PRO285 (DNA40021) in human adult and fetal tissues was examined. The following probes were used, synthesized based upon the full-length DNA40021 sequence:

Oligo 1: GGA TTC TAA TAC GAC TCA CTA TAG GGC AAA CTC TGC CCT GTG ATG TCA (SEQ ID NO: 27)

10 Oligo 2: CTA TGA AAT TAA CCC TCA CTA AAG GGA ACG AGG GCA ATT TCC ACT TAG (SEQ ID NO: 28)

In this experiment, low levels of expression were observed in the placenta and over hematopoietic cells in the mouse fetal liver. No expression was detected in either human fetal, adult or chimp lymph node and no expression was detected in human fetal or human adult spleen. These data are not fully consistent with Northern blot or PCR data, probably due to the lack of sensitivity in the *in situ* hybridization assay. It is possible that further tissues would show some expression under more sensitive conditions.

#### PRO 358 (DNA47361)

20 The expression pattern of PRO358 (DNA47361) in human adult and fetal tissues was examined. The following probes were used, synthesized based upon the full-length DNA47361 sequence:

Oligo 1: GGA TTC TAA TAC GAC TCA CTA TAG GGC TGG CAA TAA ACT GGA GAC ACT (SEQ ID NO: 29)

25 Oligo 2: CTA TGA AAT TAA CCC TCA CTA AAG GGA TTG AGT TGT TCT TGG GTT GTT (SEQ ID NO: 30)

In this experiment, expression was found in gut-associated lymphoid tissue and developing splenic white pulp in the fetus. Low level expression was seen in the pALS region of normal adult spleen. Although all other tissues were negative, it is possible that low levels of expression could be observed in other tissue types under more sensitive conditions.

30 \* \* \* \*

#### Deposit of Material

The following materials have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC):

<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
35 DNA40021-1154 (encoding PRO285)	209389	October 17, 1997

DNA42663-1154  
(encoding PRO286)

209386

October 17, 1997

DNA47361-1249

209431

November 7, 1997

This deposit was made under the provisions of the Budapest Treaty on the  
5 International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure  
and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable  
culture of the deposit for 30 years from the date of deposit. The deposit will be made available  
by ATCC under the terms of the Budapest Treaty, and subject to an agreement between  
Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the  
10 progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or  
upon laying open to the public of any U.S. or foreign patent application, whichever comes first,  
and assures availability of the progeny to one determined by the U.S. Commissioner of Patents  
and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules  
pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

15 The assignee of the present application has agreed that if a culture of the  
materials on deposit should die or be lost or destroyed when cultivated under suitable  
conditions, the materials will be promptly replaced on notification with another of the same.  
Availability of the deposited material is not to be construed as a license to practice the invention  
in contravention of the rights granted under the authority of any government in accordance with  
20 its patent laws.

The foregoing written specification is considered to be sufficient to enable one  
skilled in the art to practice the invention. The present invention is not to be limited in scope  
by the construct deposited, since the deposited embodiment is intended as a single illustration  
of certain aspects of the invention and any constructs that are functionally equivalent are within  
25 the scope of this invention. The deposit of material herein does not constitute an admission that  
the written description herein contained is inadequate to enable the practice of any aspect of the  
invention, including the best mode thereof, nor is it to be construed as limiting the scope of the  
claims to the specific illustrations that it represents. Indeed, various modifications of the  
invention in addition to those shown and described herein will become apparent to those skilled  
30 in the art from the foregoing description and fall within the scope of the appended claims.

What is claimed is:

1. Isolated nucleic acid comprising a polynucleotide sequence having at least a 95% sequence identity to (a) a DNA molecule encoding a PRO285 polypeptide having amino acid residues 27 to 839 of Fig. 1 (SEQ ID NO:1); or (b) to a DNA molecule encoding a PRO286 polypeptide having amino acid residues 27 to 825 of Fig. 3 (SEQ ID NO:3); or (c) to a DNA molecule encoding a PRO358 polypeptide having amino acids 20 to 575 of Fig. 12A-B (SEQ ID NO: 13); or (d) the complement of the DNA molecule of (a), (b), or (c).
2. The isolated nucleic acid of claim 1 comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding a PRO285 polypeptide having amino acid residues 1 to 839 of Fig. 1 (SEQ ID NO:1); or (b) to a DNA molecule encoding a PRO286 polypeptide having amino acid residues 1 to 825 of Fig. 3 (SEQ ID NO:3), or (c) the complement of the DNA molecule of (a) or (b).
3. The isolated nucleic acid of claim 1 comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding a PRO358 polypeptide comprising the sequence of amino acids 20 to 575 of Figures 12A and 12B (SEQ ID NO: 13), or (b) the complement of the DNA molecule of (a).
4. The isolated nucleic acid of claim 1 comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a PRO358 polypeptide comprising the sequence of amino acids 20 to 811 of Figures 12A and 12B (SEQ ID NO: 13), or (b) the complement of the DNA molecule of (a).
5. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO285 polypeptide having amino acid residues 1 to 839 of Fig. 1 (SEQ ID NO:1).
6. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO285 polypeptide having amino acid residues 1 to 1049 of Fig. 1 (SEQ ID NO:1).
7. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO285 polypeptide having amino acid residues 1 to 839 and 865 to 1049 of Fig. 1 (SEQ ID NO: 1).
8. The nucleic acid of claim 1 wherein said DNA comprises the nucleotide sequence starting at nucleotide position 85 of Figure 2 (the sequence of SEQ ID NO:2), or its complement.
9. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO286 polypeptide having amino acid residues 1 to 1041 of Fig. 3 (SEQ ID NO:3).
10. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO286 polypeptide having amino acid residues 1 to 825 and 849 to 1041 of Fig. 3 (SEQ ID NO:3).
11. The isolated nucleic acid of claim 1 wherein said DNA comprises the nucleotide sequence starting at nucleotide position 57 of Figure 4 (the sequence of SEQ ID NO:4), or its complement.
12. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO358 polypeptide having amino acid residues 20 to 575 of Figures 12A and 12B (SEQ ID NO:13), or the complement thereof

13. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO358 polypeptide having amino acid residues 20 to 811 of Figures 12A and 12B (SEQ ID NO: 13), or the complement thereof.

14. The isolated nucleic acid of claim 1 comprising DNA encoding a PRO358 polypeptide having amino acid residues 1 to 811 of Figures 12A and 12B (SEQ ID NO: 1), or the complement thereof.

15. An isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human Toll protein cDNA in ATCC deposit No. 209389 (DNA40021-1154), or (b) the complement of the DNA molecule of (a).

16. An isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human Toll protein cDNA in ATCC deposit No. 209386 (DNA42663-1154).

17. An isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human Toll protein cDNA in ATCC Deposit No.209431 (DNA47361-1249), or (b) the complement of the DNA molecule of (a).

18. A vector comprising the nucleic acid of claim 1.

19. The vector of claim 18 operably linked to control sequences recognized by a host cell transformed with the vector.

20. A host cell comprising the vector of claim 18.

21. The host cell of claim 20 wherein said cell is a CHO cell.

22. The host cell of claim 20 wherein said cell is an *E. coli*.

23. The host cell of claim 20 wherein said cell is a yeast cell.

24. A process for producing a Toll polypeptide comprising culturing the host cell of claim 20 under conditions suitable for expression of a polypeptide of claim 1 and recovering said polypeptide.

25. A chimeric molecule comprising a PRO285 or PRO286 or PRO358 polypeptide or a transmembrane-domain deleted or inactivated variant thereof, fused to a heterologous amino acid sequence.

26. The chimeric molecule of claim 25 wherein said heterologous amino acid sequence is an epitope tag sequence.

27. The chimeric molecule of claim 26 wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

28. An antibody which specifically binds to a polypeptide encoded by DNA 40021 or DNA42663 or DNA47361.

29. The antibody of claim 28 wherein said antibody is a monoclonal antibody.

30. The antibody of claim 29 capable of blocking the recognition of a Gram-negative or Gram-positive organism by said polypeptide.

31. An antibody which specifically binds a human TLR2 (hTLR2) receptor.

32. The antibody of claim 31 capable of blocking the activation of hTLR2 by lipopolysaccharide (LPS) of Gram-negative bacteria.

33. The antibody of claim 32 wherein said bacteria is *E. coli*.

5 34. A human TLR2 (hTLR2) variant having a deletion at the C-terminus of a native hTLR2.

35. The variant of claim 34 having 13 amino acids deleted at the C-terminus of a native hTLR2.

10 36. The variant of claim 34 having 141 amino acids deleted at the C-terminus of a native hTLR2.

37. A method of treatment of septic shock comprising administering the a patent an effective amount of an antibody of claim 28 or claim 31.

38. A composition comprising an effective amount of an antibody of claim 28 or claim 31, in admixture with a pharmaceutically acceptable carrier.

15 39. An agonist of a PRO285, or PRO286, or PRO358 polypeptide.

40. An antagonist of a PRO285, or PRO286, or PRO358 polypeptide.

&gt;&lt;MW: 120922

MVFPMWTLKRQILILFNIILISKLLGARWFPKTLPCDVTLDVPKNHVIVDCTDKHLTEIP  
GGIPTNTTNLTTLTINHIPDISPASFHRLDHLVEIDFRCNCVPIPLGSKNNMCIKRLQIKP  
RSFSGLTYLKSLYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYLG  
QNCYYRNP CYVSYSIEKDAFLNLTKLKVLSLKDNNVTAVPTVLPSTLTELYLYNNMIAKI  
QEDDFNNLNQLQILDLSGNCPRCYNAPFPCAPCKNNSPLQIPVNAFDALTELKVLRLHSN  
SLQHVPFRWFKNINKLQELDLSONFLAKEIGDAKFLHFLPSLIQLDLSFNFELOVYRASM  
NLSQAFSSLSKSLKILRIRGYVFKELKSFNLSPLHNLQNLVLDLGTNFIKIANLSMFKQF  
KRLKVIDLSVNKISPSGDSSEVGFCNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNK  
EASFMSVNESCYKYGQTLDLKNSIFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP  
LAELRYLDFSNRRLDLLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKVLOK  
LMMNDNDISSSTSRTESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISKN  
SLSFLPSGVFDGMPPNLKNLSLAKNGLKSFWSKKLQCLKNLETDLDSHNQLTTVPERLSN  
CSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLLL  
HHNRFLCTCDAVWFVWWVNHTVETIPYLATDVTGPGGAHKGQSVISLDLYTCELDLTNL  
ILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK  
DPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLENLSQSIQLSKKTVFVMTDK  
YAKTENFKIAFYLSHQRLMDEKVDVIIILIFLEKPFQKSKFLQLRKRLCGSSVLEWPTNPQ  
AHPYFWQCLKNALATDNHVAYSQVFKETV

FIG. 1

```
><insert starts here>CCCATCTCAAGCTGATCTTGGCACCTCTCATGCTCTGCTCTCTTCAACCAGACCTCTACA
TTCCATTTTGGGAAGAAGACTAAAA
><MET {trans=1-s, dir=f, res=1}>
ATGGTGTTTCCAATGTGGACACTGAAGAGACAAATTCTTATCCTTTTTTAACATAATCCTA
ATTTCCAAACTCCTTGGGGCTAGATGGTTTCCTAAAACCTCTGCCCTGTGATGCTACTCTG
GATGTTCCAAAGAACCATGTGATCGTGGACTGCACAGACAAGCATTTGACAGAAATTCCT
GGAGGTATTCCCACGAACACCACGAACCTCACCTCACCATTAACCACATACCAGACATC
TCCCCAGCGTCCTTTCACAGACTGGACCATCTGGTAGAGATCGATTTAGATGCAACTGT
GTACCTATTCCACTGGGGTCAAAAAACAACATGTGCATCAAGAGGCTGCAGATTAAACCC
AGAAGCTTTAGTGGACTCACTTATTTAAATCCCTTTACCTGGATGGAAACCAGCTACTA
GAGATACCGCAGGGCCTCCCGCTAGCTTACAGCTTCTCAGCCTTGAGGCCAACACATC
TTTTCCATCAGAAAAGAGAATCTAACAGAACTGGCCAACATAGAAATACTCTACCTGGGC
CAAACTGTTATTATCGAAATCCTTGTTATGTTTCATATTCAATAGAGAAAGATGCCTTC
CTAACTTGACAAAGTTAAAAGTGCTCTCCCTGAAAGATAACAATGTCACAGCCGTCCTT
ACTGTTTTGCCATCTACTTTAACAGAACTATATCTCTACAACAACATGATTGCAAAAATC
CAAGAAGATGATTTTAATAACCTCAACCAATTACAAATTCTTGACCTAAGTGGAAATTGC
CCTCGTTGTTATAATGCCCATTTTCTTGTCGCCGTGTAAAAATAATTCTCCCCACAG
ATCCCTGTAAGTGTCTTTGATGCGCTGACAGAATTAAAAGTTTACGTCTACACAGTAAC
TCTCTTCAAGATGTGCCCCCAAGATGGTTTAAAGAACATCAACAACTCCAGGAACCTGGAT
CTGTCCCAAACTTCTTGCCAAAGAAATTGGGGATGCTAAATTTCTGCATTTTCTCCCC
AGCCTCATCCAATTGGATCTGTCTTTCAATTTGAACTTCAGGTCTATCGTGCATCTATG
AATCTATCACAAGCATTTTCTTCACTGAAAAGCCTGAAAATTCTGCGGATCAGAGGATAT
GTCTTTAAAGAGTTGAAAAGCTTTAACCTCTCGCCATTACATAATCTTCAAATCTTGAA
GTTCTTGATCTTGGCACTAATTTATAAAAATTGCTAACCTCAGCATGTTTAAACAATTT
AAAAGACTGAAAGTCATAGATCTTTAGTGAATAAAATATCACCTTCAGGAGATTCAAGT
GAAGTTGGCTTCTGTCAAATGCCAGAACTTCTGTAGAAAGTTATGAACCCAGGTCTTG
GAACAATTATCTATTTCAGATATGATAAGTATGCAAGGAGTTGCAGATTCAAAAACAAA
GAGGCTTCTTTTCAATGTCTGTTAATGAAAGCTGCTACAAGTATGGGCAGACCTTGGATCTA
AGTAAAAATAGTATATTTTTTGTCAAGTCTCTGATTTTCAGCATCTTTCTTTCTCAAA
TGCCTGAATCTGTGAGGAAATCTCATTAGCCAACTCTTAATGGCAGTGAATTCCAACCT
TAGCAGAGCTGAGATATTTGGACTTCTCCAACAACCGGCTTGATTTACTCCATTCAACA
GCATTTGAAGAGCTTCACAACTGGAAGTTCTGGATATAAGCAGTAATAGCCATTATTTT
CAATCAGAAGGAATTACTCATATGCTAACTTTACCAAGAACCTAAAGGTTCTGCAGAAA
CTGATGATGAACGACAATGACATCTCTTCTCCACCAGCAGGACCATGGAGAGTGAGTCT
CTTAGAACTCTGGAATTGAGAGGAAATCACTTAGATGTTTTATGGAGAGAAGGTGATAAC
AGATACTTACAATTATTCAAGAATCTGCTAAAAATTAGAGGAATTAGACATCTCTAAAAAT
TCCCTAAGTTTCTTGCTTCTGGAGTTTTTGTGGTATGCCTCCAAATCTAAAGAATCTC
TCTTTGGCCAAAAATGGGCTCAAATCTTTAGTTGGAAGAACTCCAGTGTCTAAAGAAC
CTGGAACCTTTGGACCTCAGCCACAACCACTGACCACTGTCCCTGAGAGATTATCCAAC
TGTTCCAGAAGCCTCAAGAATCTGATTCTTAAGAATAATCAAATCAGGAGTCTGACGAAG
TATTTTCTACAAGATGCCTTCCAGTTGCGATATCTGGATCTCAGCTCAAATAAAATCCAG
ATGATCCAAAAGACCAGCTTCCCAGAAAATGTCCTCAACAATCTGAAGATGTTGCTTTTG
CATCATAATCGGTTTCTGTGCACCTGTGATGCTGTGTGGTTTGTCTGGTGGGTTAACCAT
ACGGAGGTGACTATTCTTACCTGGCCACAGATGTGACTTGTGTGGGGCCAGGAGCACAC
AAGGGCCAAAAGTGTGATCTCCCTGGATCTGTACACCTGTGAGTTAGATCTGACTAACCTG
ATTCTGTTCTCACTTTCCATATCTGTATCTCTTTCTCATGGTGATGATGACAGCAAGT
CACCTCTATTTCTGGGATGTGTGGTATATTTACCATTTCTGTAAGGCCAAGATAAAGGGG
TATCAGCGTCTAATATCACCAGACTGTTGCTATGATGCTTTTATTGTGTATGACACTAAA
GACCCAGCTGTGACCGAGTGGGTTTTGGCTGAGCTGGTGGCCAACTGGAAGACCCAAGA
GAGAAACATTTTAATTTATGTCTCGAGGAAAGGGACTGGTTACCAGGGCAGCCAGTTCTG
GAAAACCTTTCCAGAGCATACAGCTTAGCAAAAAGACAGTGTGTGTGATGACAGACAAG
TATGCAAAGACTGAAAATTTAAGATAGCATTTTACTTGTCCCATCAGAGGCTCATGGAT
GAAAAAGTTGATGTGATTATCTTGATATTTCTTGAGAAGCCCTTCAGAAGTCCAAGTTC
CTCCAGCTCCGGAAGAGGCTCTGTGGGAGTTCTGTCTTGTAGTGGCCAAACAAACCCGCAA
GCTCACCATACTTCTGGCAGTGTCTAAAGAACGCCCTGGCCACAGACAATCATGTGGCC
TATAGTCAGGTGTTCAAGGAAACGGTCTAGCCCTTCTTTGCAAAACACAACCTGCCTAGTT
TACCAAGGAGAGGCCTGGC
```

Figure 2



MENMFLQSSMLTCIFLLISGSCELCAEENFSRSYPCDEKKQND SVIAEC SNRR LQEV PQT  
VGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQH QNGNPGIQSNGLNITDGA  
FLNLKNLRELLLEDNQLPQIPSGLPESLTEL SLIQNNIYNITKEGISRLINLKNLYLAWN  
CYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLF LSNTQIKYISEE  
DFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNL TQLRYLNLSSTSLR  
KINAAWFKNMPHLKVLDLEFN YLVGEIVSGAFLTMLPRLEILDLSFN YIKGSYPQHINIS  
RNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLG INFIKQIDFKLFQNF SNL  
EIIYLSENRI SPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCA  
AYGKALDLSLNSIFFIGPNQFENLPDIACL NLSANSNAQVLSGTEFSAIPHVKYLDLTNN  
RLDFDNASALTELS DLEVLDLSYN SHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYT LT  
DKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRL DLSLNRLKHIPNEAFL  
NLPASLTE LHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLR TLLLS  
HNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHG NPFECTCDI  
GDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILFFFTFFITT  
MVMLAALAHHLFYWDVWFIYNVCLAKVKGYRSLSTSQT FYDAYISYDTKDASVTDWVINE  
LRYHLEESRDKNVLLCLEERDWD PGLAIIDNMQSINQSKKT VFLTKKYAKSWNFKTAF  
YLALQRLMDENMDVIIIFILLEPVLQHSQYLRLRQRICKSSILQWPDNPKAEG LFWQTLRN  
VVL TENDSRYNMYVDSIKQY

<1041 residues, 0 stop; molecular weight: 119856.26

### FIG. 3

```
><cDNA starts here>GGGTACCATTCTGCGCTGCTGCAAGTTACGGAATGAAAAATTAGAACAAACAGA
AAC
><MET {trans=1-s, dir=f, res=1}>
ATGGAACACATGTTCTTCAGTCGTCAATGCTGACCTGCATTTTCCTGCTAATATCTGGT
TCCTGTGAGTTATGCGCCGAAGAAAATTTTCTAGAAGCTATCCTTGTGATGAGAAAAAG
CAAAATGACTCAGTTATTGCAGAGTGCAGCAATCGTCGACTACAGGAAGTTCCCCAAACG
GTGGGCAAAATATGTGACAGAACTAGACCTGTCTGATAATTTATCACACACATAACGAAT
GAATCATTTCAAGGGCTGCAAAATCTCACTAAAATAAATCTAAACCACAACCCCAATGTA
CAGCACCAGAACGGAAATCCCGGTATACAATCAAATGGCTTGAATATCACAGACGGGGCA
TTCTCAACCTAAAAAACCTAAGGGAGTTACTGCTTGAAGACAACCAAGTTACCCCAAATA
CCCTCTGGTTTGCCAGAGTCTTTGACAGAACTTAGTCTAATTCAAAAACAATATATACAAC
ATAACTAAAGAGGGCATTCAAGACTTATAAACTTGAAAAATCTCTATTTGGCCTGGAAC
TGCTATTTTAACAAAGTTTGCGAGAAAACTAACATAGAAGATGGAGTATTTGAAACGCTG
ACAAATTTGGAGTTGCTATCACTATCTTTCAATTCTCTTTCACACGTGCCACCCAACTG
CCAAGCTCCCTACGCAAACTTTTTCTGAGCAACACCCAGATCAAATACATTAGTGAAGAA
GATTTCAAGGGATTGATAAATTTAACATTACTAGATTTAAGCGGGAACTGTCCGAGGTGC
TTCAATGCCCAATTTCCATGCGTGCCTTGATGGTGGTGCTTCAATTAATATAGATCGT
TTTGCTTTTCAAACTTGACCCAACCTCGATACCTAAACCTCTCTAGCACTTCCCTCAGG
AAGATTAATGCTGCCTGGTTTAAAAATATGCCTCATCTGAAGGTGCTGGATCTTGAATTC
AACTATTTAGTGGGAGAAATAGTCTCTGGGGCATTTTTAACGATGCTGCCCCGCTTAGAA
ATACCTTGACTTGTCTTTAACTATATAAAGGGGAGTTATCCACAGCATATTAATTTCC
AGAACTTCTCTAACTTTTGTCTCTACGGGCATTGCATTTAAGAGGTTATGTGTTCCAG
GAAGTCAAGAGATGATTTCCAGCCCTGATGCAGCTTCCAACTTATCGACTATCAAC
TTGGGTATTAATTTTATTAAGCAAATCGATTTCAAACCTTTCCAAAATTTCTCCAATCTG
GAAATTAATTTACTTGTGAGAAACAGAAATATCACCGTTGGTAAAAGATACCCGGCAGAGT
TATGCAAATAGTTCCTCTTTTCAACGTCATATCCGGAACGACGCTCAACAGATTTTGAG
TTGACCCACATTGCAACTTTTATCATTTCAACCGTCTTTAATAAAGCCACAATGTGCT
GCTTATGGAAGCCCTTAGATTTAAGCCTCAACAGTATTTCTTTCATTGGGCCAAACCA
TTTGAAAATCTTCTGACATTGCCTGTTTAAATCTGTCTGCAAATAGCAATGCTCAAGTG
TTAAGTGGAACTGAATTTTCAAGCATTCTCATGTCAAATATTTGGATTGACAAACAAT
AGACTAGACTTTGATAATGCTAGTGTCTTACTGAATGTCCGACTTGGAAGTTCTAGAT
CTCAGCTATAATTCACACTATTTTCAAGATAGCAGGCGTAACACATCATCTAGAATTTATT
CAAAATTTTCAAAATCTAAAAGTTTAAACTTGAGCCACAACAACATTTATACTTTAACA
GATAAGTATAACCTGGAAAGCAAGTCCCTGGTAGAATTAGTTTTCAGTGGCAATCGCCTT
GACATTTTGTGGAATGATGATGACAACAGGTATATCTCCATTTTCAAAGGTCTCAAGAAT
CTGACACGTCTGGATTATCCCTTAATAGGCTGAAGCACATCCCAATGAAGCATTCTT
AATTTGCCAGCGAGTCTCACTGAACTACATATAAATGATAATATGTTAAAGTTTAAAC
TGGACATTACTCCAGCAGTTTCTCGTCTCGAGTTGCTTGACTTACGTGGAAACAACTA
CTCTTTTAACTGATAGCCTATCTGACTTTACATCTTCCCTTCGGCACTGCTGCTGAGT
CATAACAGGATTTCCACCTACCCCTCTGGCTTTCTTTCTGAAGTCAGTAGTCTGAAGCAC
CTCGATTTAAGTTCCAATCTGCTAAAAACAATCAACAAATCCGCACTTGAACTAAGACC
ACCACCAAATTTATCTATGTTGGAATACACGGAACCCCTTTGAATGCACCTGTGACATT
GGAGATTTCCGAAGATGGATGGATGAACATCTGAATGTCAAATTTCCAGACTGGTAGAT
GTCATTTGTGCCAGTCTTGGGGATCAAAGAGGGAAGAGTATTGTGAGTCTGGAGCTAACA
ACTTGTGTTTTCAGATGTCAGTGCAGTGATATTATTTTCTTCAAGTCTTTATCACCACC
ATGGTTATGTTGGCTGCCCTGGCTCACCATTGTGTTTACTGGGATGTTGGTTTATATAT
AATGTGTGTTTAGCTAAGGTAAAAGGCTACAGGTCTCTTCCACATCCCAAACTTTCTAT
GATGCTTACATTTCTTATGACACCAAAGATGCCTCTGTTACTGACTGGGTGATAAATGAG
```

## Sequence ss.DNA42663

CTGCGCTACACCTTGAAGAGAGCCGAGACAAAAACGTTCTCCTTTGTCTAGAGGAGAGG  
GATTGGGACCCGGGATTGGCCATCATCGACAACCTCATGCAGAGCATCAACCAAAGCAAG  
AAAACAGTATTTGTTTTAACCAAAAAATATGCAAAAAGCTGGAACTTTAAAACAGCTTTT  
TACTTGGCTTTGCAGAGGCTAATGGATGAGAACATGGATGTGATTATATTTATCCTGCTG  
GAGCCAGTGTTACAGCATTTCTCAGTATTGAGGCTACGGCAGCGGATCTGTAAGAGCTCC  
ATCCTCCAGTGGCCTGACAACCCGAAGGCAGAAGGCTTGTTTTGGCAAACCTCTGAGAAAT  
GTGGTCTTGACTGAAAATGATTACCGGTATAACAATATGTATGTCGATTCCATTAAGCAA  
TACTAACTGACGTAAAGTCATGATTTTCGCGCCATAATAAAGATGCAAAGGAATGACATTT  
CTGTATTAGTTATCTATTGCTATGTAACAAATTATCCCAAACTTAGTGGTTTTAAACAA  
CACATTTGCTGGCCACAGTTTTTGAGGGTCAGGAGTCCAGGCCAGCATAACTGGGTCC  
TCTGCTCAGGGTGTCTCAGAGGCTGCAATGTAGGTGTTACCAGAGACATAGGCATCACT  
GGGGTCACACTCATGTGGTTGTTTTCTGGATTCAATTCCTCCTGGGCTATTGGCCAAAGG  
CTATACTCATGTAAGCCATGCGAGCCTCTCCCAAGGCAGCTTGCTTCATCAGAGCTAG  
CAAAAAAGAGAGGTTGCTAGCAAGATGAAGTCACAATCTTTTGAATCGAATCAAAAAAG  
TGATATCTCATCACTTTGGCCATATTCTATTTGTTAGAAGTAAACCACAGGTCCCACCAG  
CTCCATGGGAGTGACCACCTCAGTCCAGGGAAAAACAGCTGAAGACCAAGATGGTGAGCTC  
TGATTGCTTCAGTTGGTCATCAACTATTTCCCTTGACTGCTGCTGCTGGGATGGCCTGCT  
ATCTTGATGATAGATTGTGAATATCAGGAGGCAGGGATCACTGTGGACCATCTTAGCAGT  
TGACCTAACACATCTTCTTTCAATATCTAAGAACTTTTGCCACTGTGACTAATGGTCTT  
AATATTAAGCTGTTGTTTTATTTATCATATATCTATGGCTACATGCTTATATTATGCTG  
TGGTTGCGTTCGGTTTTATTACAGTTGCTTTTACAAATATTTGCTGTAACATTTGACTT  
CTAAGGTTTAGATGCCATTTAAGAACTGAGATGGATAGCTTTTAAAGCATCTTTTACTTC  
TTACCATTTTTTAAAAGTATGCAGCTAAATTCGAAGCTTTTGGTCTATATTGTTAATTGC  
CATTGCTGTAAATCTTAAATGAATGAATAAAAAATGTTTCATTTTACAAAAA

AAA

.6 / .18




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




Figure 7






FIG. 8A




FIG. 8B




FIG. 9

GTTATGCCTAGAAAACATTTCTCAAGAATTAGAATTACGATATGCTGTCAAACACAATGA  
CTTATTTGAACCTCTTTTATTTGTAGGTTGAAGCACTGGACAATGCCACATACTTTGTGG  
ATGGTGTGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAAGAATCCTCCAATCAGGCT  
TCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCAGGATCTTTAAACTCCATT  
CCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCCAACAACAGGATCACCTAC  
ATTAGCAACAGTGACCTACAGAGGTGTGTGAACCTCCAGGCTCTGGTGCTGACATCCAAT  
GGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGCAGTCTTGAACATTTAGAC  
TTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTCAAGCCCCCTTTCTTCTTTA  
ACATTCTTAACTTACTGGGAAATCCTTACAAAACCCTAGGGGAAACATCTCTTTTTTCT  
CATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATATGGACACCTTCACTAAGATTCAA  
AGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAGATTGATGCTTCAGATCTA  
CAGAGCTATGAGCCAAAAGTTTGAAGTCAATTCAGAATGTAAGTCATCTGATCCTTCAT  
ATGAAGCAGCATATTTTACTGCTGGAGATTTTTGTAGATGTTACAAGTTCCGTGGAATGT  
TTGGAAGTGCAGAGATACTGATTTGGACACTTTCATTTTTTCAGAACTATCCACTGGTGAA  
ACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAAATCACCGATGAAAGTTTG  
TTTCAGGTTATGAACTTTTGAATCAGATTTCTGGATTGTTAGAATTAGAGTTTGATGAC  
TGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAATGACAGAGTTATAGATCCA  
GGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCAAGGTTTTACTTATTTTAT  
GATCTGAGCACTTTATATTCACCTACAGAAAGAGTTAAAAGAATCACAGTAGAAAACAGT  
AAAGTTTTTCTGGTTCCTTGTTTACTTTCACAACATTTAAAATCATTAGAATACTTGGAT  
CTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCAGCCTGTGAGGATGCCTGG  
CCCTCTCTACAACTTTAATTTTAAGGCAAAATCATTTGGCATCATTGGAAAAAACC GGA  
GAGACTTTGCTCACTCTGAAAACTTGACTAACATTGATATCAGTAAGAATAGTTTTTCAT  
TCTATGCCTGAACTTTGTCAGTGGCCAGAAAAGATGAAATATTTGAACTTATCCAGCACA  
CGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAAATTTTAGATGTTAGCAAC  
AACAATCTCAATTTATTTTCTTTGAATTTGCCGCAACTCAAAGAACTTTATATTTCCAGA  
AATAAGTTGATGACTCTACCAGATGCCTCCCTCTTACCCATGTTACTAGTATTGAAAATC  
AGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGACTCATTTACACACTGAAG  
ACTTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAATTCCTCTCCTTCACTCAG  
GAGCAGCAAGCACTGGCCAAAGTCTTGATTGATTGGCCAGCAAATTACCTGTGTGACTCT  
CCATCCCATGTGCGTGGCCAGCAGGTTTCAGGATGTCCGCCTCTCGGTGTCCGAATGTCAC  
AGGACAGCACTGGTGTCTGGCATGTGCTGTGCTCTGTTCTCTGCTGATCCTGCTCACGGGG  
GTCCTGTGCCACCGTTTTCCATGGCCTGTGGTATATGAAAATGATGTGGGCCTGGCTCCAG  
GCCAAAAGGAAGCCCAGGAAAGCTCCCAGCAGGAACATCTGCTATGATGCATTTGTTTTCT  
TACAGTGAGCGGGATGCCTACTGGGTGGAGAACCTTATGGTCCAGGAGCTGGAGAACTTC  
AATCCCCCTTCAAGTTGTGTCTTCATAAGCGGGACTTCATTCTGGCAAGTGGATCATT  
GACAATATCATTGACTCCATTGAAAAGAGCCACAAAACGTCTTTGTGCTTTCTGAAAAC  
TTTGTGAAGAGTGAGTGGTGCAAGTATGAACTGGACTTCTCCATTTCGGTCTTTTTTGAT  
GAGAACAAATGATGCTGCCATTCTCATTCTTCTGGAGCCCATTGAGAAAAAAGCCATTCCC  
CAGCGCTTCTGCAAGCTGCGGAAGATAATGAACACCAAGACCTACCTGGAGTGGCCCATG  
GACGAGGCTCAGCGGGAAGGATTTTGGGTAAATCTGAGAGCTGCGATAAAGTCCTAGGTT  
CCCATATTTAAGACCAGTCTTTGTCTAGTTGGGATCTTTATGTCACTAGTTATAGTTAAG  
TTCATTTCAGACATAATTATATAAAAACTACGTGGATGTACCGTCATTTGAGGACTTGCTT  
ACTAAACTACAAAACCTTCAA

FIG. 10

MPHTLWMVWVLGVIIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSDDL  
SNNRITYISNSDLQRCVNLOALVLTSNGINTIEEDSFSSLSLEHLDSLNYLSNLSSS  
WFKPLSSLTFLNLLGNPYKTLGETSLFSLTKLQILRVGNMDTFTKIQRKDFAGLTFLE  
ELEIDASDLQSYEPKSLKSIQNVSHLILHMKQHILLEIFVDVTSSVECLELRDLDLT  
FHFSELSTGETNSLIKKFTFRNVKITDESLEFQVMKLLNQISGLLELEFDDCTLNGVGNF  
RASDNRVIDDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCL  
LSQHLKSLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLSLEKTGETLLTLK  
NLTNIDISKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKLEILDVSNNNLNLF  
SLNLPQLKELYISRKNLMTLPDASLLPMLLVLKISRNAITTFSEQLDSFHTLKTLEAG  
GNNFICSCEFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTAL  
VSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSE  
RDAYWVENLMVQELFNFPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSNFV  
KSEWCKYELDFSHFRLFDENNDAAILILLEPIEKKAIPQRFCCLRKIMNTKTYLEWPMD  
EAQREGFWVNLRAAIKS

**FIG. 11**

(SEQ ID NO: 1)  
 Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu 30  
 1 5 10 15 20 25  
 Met Thr Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu 60  
 35 40 45 50 55  
 Phe Gln Leu Gln Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys His Asn Arg Ile Gln Gln Leu Asp Leu Lys 90  
 65 70 75 80 85  
 Thr Phe Glu Phe Asn Lys Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr Trp Tyr Leu Leu Ala Gly Leu Arg 120  
 95 100 105 110 115  
 Tyr Leu Asp Leu Ser Phe Asn Asp Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu Glu Ile Leu Gly Leu Ser 150  
 125 130 135 140 145  
 Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr Leu Pro His Tyr 180  
 155 160 165 170 175  
 Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg Asp Gly 210  
 185 190 195 200 205  
 Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu 240  
 215 220 225 230 235  
 Asn Ala Lys Thr Ser Val Leu Leu Asn Lys Val Asp Leu Leu Trp Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser 270  
 245 250 255 260 265  
 Val Glu His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg 300  
 275 280 285 290 295  
 Thr Ile Lys Leu Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr Leu Leu Thr Lys Met Asp Ile Glu Asn 330  
 305 310 315 320 325  
 Leu Thr Ile Ser Asn Ala Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr Leu Asn Phe Ala Asn Asn Ile Leu 360  
 335 340 345 350 355  
 Thr Asp Glu Leu Phe Lys Arg Thr Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu Glu Thr Leu Ser Leu Val 390  
 365 370 375 380 385  
 Ser Cys Phe Ala Asn Thr Pro Leu Glu His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn Cys Ser Trp Pro 420  
 395 400 405 410 415

Figure 12A

Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu Asp Leu  
 425 430 435 440 445 450  
 Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp  
 455 460 465 470 475 480  
 Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser  
 485 490 495 500 505 510  
 Cys Gln Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser  
 515 520 525 530 535 540  
 Glu Val Met Met Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg Gly Thr Arg Leu Lys Asp Val His Leu His  
 545 550 555 560 565 570  
 Glu Leu Ser Cys Asn Thr Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu Ala Val Ala Phe Cys Cys Leu His  
 575 580 585 590 595 600  
 Phe Asp Leu Pro Trp Tyr Leu Arg Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr Gln Glu Gln Leu Lys Arg  
 605 610 615 620 625 630  
 Asn Val Arg Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu Glu Lys Glu Asp  
 635 640 645 650 655 660  
 Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys Ser Tyr  
 665 670 675 680 685 690  
 Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu  
 695 700 705 710 715 720  
 Asn Ser Asp His Ile Ile Leu Ile Leu Glu Pro Ile Pro Phe Tyr Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu  
 725 730 735 740 745 750  
 Lys Lys Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu  
 755 760 765 770 775 780  
 Ala Thr Arg Glu Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Ser Arg Gly Ser Thr Ile Ser Leu Met Arg Thr Asp Cys  
 785 790 795 800 805 810  
 Leu  
 811

Figure 12B

17 / 18

(SEQ ID NO: 2)

```
GAATCATCCA CGCACCTGCA GCTCTGCTGA GAGAGTGCAA GCCGTGGGGG TTTTGAGCTC ATCTTCATCA TTCATATGAG GAAATAAGTG GTAAATCCT 100
<MET {trans=1-s, dir=f, res=1}>
TGGAATATACA ATGAGACTCA TCAGAAACAT TTACATATTT TGTAGTATTG TTATGACAGC AGAGGGTGAT GCTCCAGAGC TGCCAGAAGA AAGGGAAC TG 200
ATGACCAACT GCTCCAACAT GTCTCTAAGA AAGGTTCCCG CAGACTTGAC CCAGCCACA ACGACACTGG ATTTATCCTA TAACCTCCTT TTTCAACTCC 300
AGAGTTCAGA TTTTCATTCT GTCTCCAAAC TGAGAGTTTT GATTCTATGC CATAACAGAA TTCAACAGCT GGAATCTAAA ACCTTTGAAT TCAACAAGGA 400
GTTAAGATAT TTAGATTGTT CTAATAACAG ACTGAAGAGT GTAAC TTGTTAGT AGGTCTCAGG TATTAGATC TTTCTTTTAA TGACTTTGAC 500
ACCATGCCTA TCTGTGAGGA AGCTGGCAAC ATGTCACACC TGGAAATCCT AGGTTTGAGT GGGGCAAAAA TACAAAAATC AGATTTCAG AAAATTGCTC 600
ATCTGCATCT AAATACTGTC TTCTTAGGAT TCAGAACTCT TCCTCATTAT GAAGAAAGTA GCCTGCCCAT CTTAAACACA ACAAAACTGC ACATTGTTTT 700
ACCAATGGAC ACAAAATTCT GGGTTCCTTT GCGTGATGGA ATCAAGACTT CAAAAATATT AGAAATGACA AATATAGATG GCAAAAAGCCA ATTTGTAAGT 800
TATGAAATGC AACGAAATCT TAGTTTAGAA AATGCTAAGA CATCGGTTCT ATTGCTTAAT AAAGTTGATT TACTCTGGA CGACCTTTTC CTTATCTTAC 900
AATTGTTTG GCATACATCA GTGGAACACT TTCAGATCCG AAATGTGACT TTTGGTGGTA AGGCTTATCT TGACCACAAAT TCATTGACT ACTCAAATAC 1000
TGTAATGAGA ACTATAAAAT TGGAGCATGT ACATTTGAGA GTGTTTACA TTCAACAGGA TAAATCTAT TTGCTTTTGA CCAAAATGGA CATAGAAAAAC 1100
CTGACAAATAT CAAATGCACA AATGCCACAC ATGCTTTTCC CGAATTATCC TACGAAATTC CAATATTTAA ATTTTGCCAA TAATATCTTA ACAGACGAGT 1200
TGTTTAAAG AACTATCCAA CTGCCCTCACT TGAAAACTCT CATTTTGAAT GGCAATAAAC TGGAGACACT TTCTTTAGTA AGTTGCTTTG CTAACAACAC 1300
ACCCTTGGAA CACTTGGATC TGAGTCAAAA TCTATTACAA CATAAAAATG ATGAAAATTG CTCATGGCCA GAAACTGTGG TCAATATGAA TCTGTCATAC 1400
AATAAAATTGT CTGATTCTGT CTTCAGGTGC TTGCCCAAAA GTATTCAAAT ACTTGACCTA AATAATAACC AAATCCAAAC TGTACCTAAA GAGACTATTC 1500
ATCTGATGC CTTACGAGAA CTAAATATTG CATTTAAATT TCTAACTGAT CTCCCTGGAT GCAGTCATTT CAGTAGACTT TCAGTTCTGA ACATTGAAAT 1600
GAACTTCATT CTCAGCCCCAT CTCTGGATT TGTTCAGAGC TGCCAGGAAG TTAAAACTCT AAATGCGGGA AGAAATCCAT TCCGGGTGTAC CTGTGAATTA 1700
AAAAAATTCA TTCAGCTTGA AACATATTCA GAGGTCATGA TGGTTGGATG GTCAGATTCA TACACCTGTG AATACCCCTT AAACCTAAGG GGAAC TAGGT 1800
```

FIG. 13A

18 / 18

TAAAGACGT TCATCTCCAC GAATTATCTT GCAACACAGC TCTGTTGATT GTCACCAATTG TGGTTATTAT GCTAGTTCG GGGTTGGCTG TGGCCTTCTG 1900  
CTGTCTCCAC TTTGATCTGC CCTGGTATCT CAGGATGCTA GGTC AATGCA CACAAACATG GCACAGGGTT AGGAAAACAA CCCAAGAACAA ACTCAAGAGA 2000  
AATGTCGAT TCCACGCAAT TATTTCATAC AGTGAACATG ATTCTCTGTG GGTGAAGAAT GAATTGATCC CCAATCTAGA GAAGGAAGAT GGTCTCTATCT 2100  
TGATTGTCCT TTATGAAAGC TACTTTGACC CTGGCAAAAG CATTAGTGAA AATATTGTAA GCTTCATTGA GAAAAGCTAT AAGTCCATCT TTGTTTTGTC 2200  
TCCCAACTTT GTCCAGAATG AGTGGTGCCA TTATGAATTC TACTTTGCCC ACCACAATCT CTTCCATGAA AATTCTGATC ATATAATTCT TATCTTACTG 2300  
GAACCCATTC CATTCTATTG CATTCCCACC AGGTATCATA AACTGAAAGC TCTCCTGGAA AAAAAAGCAT ACTTGGAAATG GCCCAAGGAT AGCGGTAAT 2400  
GTGGGCTTTT CTGGGCAAAAC CTTGAGCTG CTATTAAATGT TAATGTATTA GCCACCAGAG AAATGTATGA ACTGCAGACA TTCACAGAGT TAAATGAAGA 2500  
GTCTCGAGGT TCTACAAATCT CTCTGATGAG AACAGATTGT CTA TAA AATC CCACAGTCCT TGGGAAGTTG GGGACCACAT ACACCTGTTGG GATGTACATT 2600  
GATACAACCT TTATGATGC AATTGACAA TATTTATTAA AATAAAAAAT GGTATTCCC TTCAATATCAG TTTCTAGAAG GATTTCTAAG AATGTATCCT 2700  
ATAGAAACAC CTTCAACAAGT TTATAAGGC TTATGGAAAA AGGTCTTCAT CCCAGGATTG TTTAFAATCA TGAAAAATGT GGCCAGGTGC AGTGGCTCAC 2800  
TCTTGTAAATC CCAGCACTAT GGGAGGCCAA GGTGGGTGAC CCACGAGGTC AAGAGATGGA GACCATCCTG GCCAACATGG TGAAACCCCTG TCTCTACTAA 2900  
AAATACAAAA ATTAGCTGGG CGTGATGGTG CAGCCTGTA GTCCCAGCTA CTTGGGAGGC TGAGGCAGGA GAATCGCTTG AACCCGGGAG GTGGCAGTTG 3000  
CAGTGAGCTG AGATCGAGCC ACTGCACTCC AGCCTGGTGA CAGAGCGAGA CTCCATCTCA AAAAAAGAA AAAAAAATAA GAAAAAATG GAAAAACATCC 3100  
TCATGGCCAC AAAATAAGGT CTAATTCAAT AAATTATAGT ACATTAAATGT AATATAATAT TACATGCCAC TAAAAAGAAT AAGGTAGCTG TATATTTCT 3200  
GGTATGGAAA AAACATATTA ATATGTTATA AACTATTAGG TTGGTGCAAA ACTAATTGTG GTTTTTGCCA TTGAATGGC ATTGAATAA AAGGTGTAAG 3300  
AAATCTATAC CAGATGTAGT AACAGTGGT TGGGTCTGGG AGGTGGATT ACAGGGAGCA TTTGATTTCT ATGTTGTGTA TTTCTATAAT GTTTGAATTG 3400  
TTTAGAATGA ATCTGTATT CTTTATAAG TAGAAAAAATAA ATAAAGATAG TTTTACAGC CT 3462

FIG. 13B



of at least 12 amino acids to seq.12, fusion protein comprising said protein, binding compound and/or antibody specific for said protein, nucleic acids encoding said protein, expression vector comprising the nucleic acid, host transformed with the vector, and a method for producing said peptide using the transformed host.

6. Claims: 6, and 10-16 partially

Substantially pure recombinant DTLR7 protein or peptides which exhibit at least 85% sequence identity over a length of at least 12 amino acids to seq.16 or 18, fusion protein comprising said protein, binding compound and/or antibody specific for said protein, nucleic acids encoding said protein, expression vector comprising the nucleic acid, host transformed with the vector, and a method for producing said peptide using the transformed host.

7. Claims: 7, and 10-16 partially

Substantially pure recombinant DTLR8 protein or peptides which exhibit at least 85% sequence identity over a length of at least 12 amino acids to seq.32, fusion protein comprising said protein, binding compound and/or antibody specific for said protein, nucleic acids encoding said protein, expression vector comprising the nucleic acid, host transformed with the vector, and a method for producing said peptide using the transformed host.

8. Claims: 8, and 10-16 partially

Substantially pure recombinant DTLR9 protein or peptides which exhibit at least 85% sequence identity over a length of at least 12 amino acids to seq.22, fusion protein comprising said protein, binding compound and/or antibody specific for said protein, nucleic acids encoding said protein, expression vector comprising the nucleic acid, host transformed with the vector, and a method for producing said peptide using the transformed host.

9. Claims: 9, and 10-16 partially

Substantially pure recombinant DTLR10 protein or peptides which exhibit at least 85% sequence identity over a length of at least 12 amino acids to seq.34, fusion protein comprising said protein, binding compound and/or antibody specific for said protein, nucleic acids encoding said protein, expression vector comprising the nucleic acid, host transformed with the vector, and a method for producing said peptide using the transformed host.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/08979

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9802557 A	22-01-1998	AU 3514997 A	09-02-1998

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/21141

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	1, 2, 5-8, 15, 18-24, 28-30, 37, 38
	No:	Claims	
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1, 2, 5-8, 15, 18-24, 28-30, 37, 38
Industrial applicability (IA)	Yes:	Claims	1, 2, 5-8, 15, 18-24, 28-30, 38
	No:	Claims	

**2. Citations and explanations**

**see separate sheet**

**VI. Certain documents cited**

**1. Certain published documents (Rule 70.10)**

and / or

**2. Non-written disclosures (Rule 70.9)**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/21141

**Citations**

The documents mentioned in this International Preliminary Examination Report (IPER) are numbered as in the International Search Report dated 22.04.99, i.e. **D1** and **D2** correspond to the first and the last document of the search report, respectively.

**Re ITEM II (Priority)**

The priority documents pertaining to the present application were not available at the time this IPER was established.

**Re ITEM III (Non-establishment of opinion)**

- 1 The International Preliminary Examining Authority (IPEA) agrees with the objection put forward by the International Searching Authority (ISA) as to lack of unity (Rule 13 PCT) and considers that the present application relates to 4 inventions. In response to an invitation, the Applicant did not pay additional search fees. Consequently, international search and preliminary examination have been restricted to the subject-matter of claims 5-8, 15 and partially claims 1, 2, 18-30 and 37-40 ("PRO285", SEQ ID NOs:1 and 2) which the ISA identified as invention 1.
- 2 No search report was established for the subject-matter of claims 39 and 40 (agonists and antagonists). Consequently, preliminary examination has not been carried out for said claims (Rule 66.1(e) PCT). The International Preliminary Examining Authority (IPEA) agrees with the objection put forward by the International Searching Authority (ISA) as to insufficiency of disclosure concerning the subject-matter of claims 39 and 40 (Art. 5 PCT).
- 3 No examination of the claimed invention in respect of claims 25-27 can be carried out. A "transmembrane-domain deleted or inactivated variant" of "PRO285" (SEQ ID NO:1) is not disclosed in present application (Art. 5 PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/21141

- 4 Claim 37 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT (*in vivo* treatment or diagnostic methods on the human or animal body). Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of that claim (Art. 34(4)(a)(i) PCT).

For the assessment of the present claim 37 on the question whether they are industrially applicable, no unified criteria exist among the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but will allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

- 5 In summary, international preliminary examination has been restricted to the subject-matter of claims 5-8, 15 and partially claims 1, 2, 18-24, 28-30, 37, 38.

**Re ITEM V (Novelty, inventive step, industrial applicability)**

**1 Summary of the present application**

The present application is related to an isolated nucleic acid (SEQ ID NO:2) and a protein designated "PRO285" having the amino acid sequence of SEQ ID NO:1.

**3 Novelty (Art. 33(2) PCT)**

The subject-matter of claims 1, 2, 5-8, 15, 18-24, 28-30, 37 and 38 has not been made available to the public by any of the available prior art documents and can therefore be regarded as novel.

**3 Inventive step (Art. 33(3) PCT)**

- 3.1 Due to the important role of Toll proteins in the immune response there is a clear need in the art for the identification of human Toll genes/proteins that can be utilized in the development of therapeutics for disorders in the immune response (see e.g. **D1**, p. 396, last par.).
- 3.2 The closest prior art concerning claims 1, 2, 5-8, 15, 18-24, 28-30, 37 and 38 is **D1**. **D1** discloses the nucleic acid and peptide sequence of a human homologue of the *Drosophila* Toll protein. The gene of **D1** as well as the "PRO285" gene (SEQ ID NO:2) of present application were identified by using standard methods well known in the art: search for homologue sequences in EST database using *Drosophila* Toll sequences, isolation of the desired gene from a human cDNA library, e.g. brain, placenta ect. (see **D1**, p. 396, Methods and Example 1 of present application).
- 3.3 The presence of an inventive step cannot be acknowledged for the subject-matter of the examined claims as the skilled person would be prompted to use an already known nucleotide sequence of the *Drosophila* Toll gene or the human Toll gene disclosed in **D1** in a manner described in **D1** and thus arrive at the subject-matter of claims 1, 2, 5-8, 15, 18-24, 28-30, 37 and 38 without the exercise of inventive skill.

**4 Industrial applicability (Art. 33(4) PCT)**

Claims 1, 2, 5-8, 15, 18-24, 28-30 and 38 meet the criteria as set forth by Art. 33(4) PCT.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US98/21141

**Re ITEM VI                      Certain published documents (Rule 70.10)**

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO-A-9850547	12.11.98	07.05.98	07.05.97

Said document has been published after the filing date of the present application and does therefore not constitute prior art in the meaning of Rule 64(1)(b) PCT. However, **D2** (WO-A-9850547) claims an earlier priority than the present application and will therefore become of relevance for the novelty of the claimed subject-matter during regional phase examination.

**Re ITEM VIII                      (Certain observations on the international application)**

- 1 The sequence of SEQ ID NO:2 corresponds to the *complete* sequence of Fig. 2 and not just the sequence "starting at nucleotide position 85 of Fig. 2". Claim 8 is therefore regarded as unclear (Art. 6 PCT).
- 2 The designations "PRO285" (claim 25) and "DNA 40021" (claim 28) could not be found in the available prior art documents. Therefore, "PRO285" and "DNA 40021" are regarded as an internal designation which do not provide a technical teaching to the skilled person. Claims referring to a product defined by said designation only therefore lack clarity (Art. 6 PCT). The appropriate SEQ ID NO or ATCC deposit No. is not given in claims 25 and 28, respectively. Any claim directly or indirectly depending on the unclear subject-matter of claims 25 and 28 does also not satisfy the requirements of Art. 6 PCT.

RECEIVED

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

FEB 11 2000

To:

MARSCHANG, Diane L.  
GENENTECH, INC.  
1 DNA Way  
South San Francisco, CA 94080-4990  
ETATS-UNIS D'AMERIQUE

GENENTECH, INC.  
LEGAL DEPT.

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT  
(PCT Rule 71.1)

Date of mailing  
(day/month/year)

02.02.00

Applicant's or agent's file reference  
11669.53WO01

P1154R2

## IMPORTANT NOTIFICATION

International application No.  
PCT/US98/21141International filing date (day/month/year)  
07/10/1998Priority date (day/month/year)  
17/10/1997

Applicant

GENENTECH, INC. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

 European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Vullo, C

Tel. +49 89 2399-8061





# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>11669.53WO01</b>	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/US98/21141</b>	International filing date (day/month/year) <b>07/10/1998</b>	Priority date (day/month/year) <b>17/10/1997</b>	
International Patent Classification (IPC) or national classification and IPC <b>C12N15/12</b>			
Applicant <b>GENENTECH, INC. et al.</b>			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 8 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of    sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I    <input checked="" type="checkbox"/> Basis of the report</li> <li>II   <input checked="" type="checkbox"/> Priority</li> <li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV   <input type="checkbox"/> Lack of unity of invention</li> <li>V    <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI   <input checked="" type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>			
Date of submission of the demand  <b>14/05/1999</b>		Date of completion of this report  <div style="text-align: right; font-size: 1.2em;"><b>0 2. 02. 00</b></div>	
Name and mailing address of the international preliminary examining authority:  <div style="display: flex; align-items: center;"> <div>             European Patent Office              D-80298 Munich              Tel. +49 89 2399 - 0 Tx: 523656 epmu d              Fax: +49 89 2399 - 4465           </div> </div>		Authorized officer  <b>Herrmann, K</b>  Telephone No. +49 89 2399 2670	



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US98/21141

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

### Description, pages:

1-56 as originally filed

### Claims, No.:

1-40 as originally filed

### Drawings, sheets:

1/21-21/21 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
  - ☐ translation of the earlier application whose priority has been claimed.
2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/21141

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 3, 4, 9-14, 16, 17, 25-27, 31-36, 39, 40 and partially 1, 2, 18-30, 37, 38.

because:

- ☒ the said international application, or the said claims Nos. 37 with respect to industrial applicability relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☒ the claims, or said claims Nos. 25-27 are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 3, 4, 9-14, 16, 17, 31-36, 39, 40 and partially 1, 2, 18-30, 37, 38.